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ALBRECHT DÜRER'S MELANCHOLIA
 
 
“Depression has been labeled the common cold of psychopathology. This comparison is unfortunate, 
for it conveys the impression of a frequent but mild complaint. In reality ... depression is not only the 
 
 
  
most frequent mental health problem, but is among the most serious”.
PAUL GILBERT, Depression: The Evolution of Powerlessness
“Heavy thoughts bring on ph
MARTIN LUTHER, 1483
 
 
 
 
ysical maladies”. 
-1546 
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1 1. SUMMARY 
1. SUMMARY 
In clinical use, the term depression is used to describe a cluster of symptoms 
persisting over a period of at least 2 weeks, which involves significant changes in 
mood, thinking, behaviour, and activity. Besides those changes, both painful and 
non-painful somatic symptoms essentially characterize clinical states of depression, 
in a way that they are considered as a core component of it. There is growing 
evidence in the literature that, when somatic manifestations, especially painful ones, 
accompany the already debilitating affective and cognitive symptoms of major 
depression, the course of the disease can be more severe, implying worse therapy 
outcomes, higher rates of relapse, chronicity or morbidity, increased economic and 
social burden, as well as impaired functional status and quality of life for the affected 
subjects.  
The purpose of the current study was to broaden our understanding for the role of 
somatic symptoms as regards the treatment outcome of a major depressive episode, 
as well as to test the hypothesis that the individualized acute phase inpatient 
therapy for a major depressive episode is beneficial in terms of effectiveness and 
good tolerated by the patients.  
The current sample consisted of 773 inpatients, who met the DSM-IV criteria for a 
major depressive disorder. Patients with organic origin of depression were excluded. 
Our sample was a subset of patients of the large naturalistic, prospective, 
multicentre study, which was performed in 12 psychiatric hospitals of the German 
research network on depression and suicidality (five district and seven psychiatric 
university hospitals) in Germany.  
All subjects were treated in inpatient clinical settings, according to the international 
established guidelines for the treatment of major depression. Besides medication, 
including various antidepressants, neuroleptics, tranquillizers, hypnotics and other 
psychopharmacologic compounds, patients also received non-pharmacologic 
treatments, such as psychotherapy, biological treatments, and physiotherapy, when 
  
 
2 1. SUMMARY 
needed. In the framework of the multicentre study, they were assessed with specific 
clinical management tools biweekly from admission to discharge and in one- and 
four-year follow-up. Our data were provided by assessments with various 
psychopathological rating scales relevant to severity of depression (HAMD-17 
scoring), health related quality of life (SF-36 subscales and total score, FLZ, and GAF), 
as well as the side effect burden of the medication (UKU, Impairment of daily 
performance due to medication rated by patient and by clinician). Somatic symptom 
scoring was attained by adding HAMD items 4, 5, 6, 11, 12, 13, 14, and 16. HAMD 
item 13 was also separately evaluated to assess pain. All data used in our analysis 
were collected at the time of admission and at discharge. 
The majority of our patients suffered from moderate to severe depression, with a 
mean HAMD-17 score 21.79 at baseline. All of them (100%) had positive HAMD 
somatic scoring, while 677 of them (87.5%) suffered from painful somatic 
manifestations at admission. Paired samples t-tests revealed statistically significant 
difference of almost all pre- vs. posttreatment values. Posttreatment somatic 
symptoms were eliminated in 65 patients and pain in 215 of them. The mean HAMD-
17 total score at final visit decreased to 9.09. Mean somatic symptom scoring 
decreased approximately to the half of its initial value. At the end of the acute 
therapy phase, remission was finally achieved at 45%, and partial response at 24.2% 
of the subjects. Parallel, a statistically significant raise in life satisfaction and almost 
all health related quality of life measures was observed.  
Multiple statistical correlations of pre- and posttreatment values revealed important 
associations. More somatic symptoms at baseline indicated more severe depression 
and a lower level of functioning. Pain in specific, besides correlating to increased 
severity of disease, also affected the quality of life and the side effect burden. 
Furthermore, residual somatic symptoms indicated, besides a more severe 
depression, also a lower quality of life and a higher side-effect burden 
posttreatment. Side-effects, however, did not seem to affect, at least directly, the 
quality of life. 
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In order to explore the impact of severity of depression on the other studied 
parameters (somatic symptoms, total SF-36 and FLZ quality of life), we divided 
patients into three groups (mild, moderate and severe depressed). Although all the 
three groups showed an equal improvement in quality of life at endpoint, we found 
that patients with more severe depression had a higher somatic symptom scoring 
before treatment and vice versa.  
In the effort to assess the influence of somatic symptoms at baseline on the other 
studied parameters (quality of life, treatment outcome), the sample was divided 
according to somatic symptom scoring in two groups: in patients with mild and with 
severe somatic manifestations. Chi-Square Tests revealed significant correlation of 
severity of somatic symptoms at baseline with severity of disease, but no significant 
correlation with response, remission, TOTAL SF-36, FLZ scores. However, it is 
important to mention that pain at baseline showed a significant correlation to lower 
remission rates. 
We also divided our patients in three groups according to treatment outcome, 
remitters, responders and non-responders, with respect to the established criteria 
for remission and response. Oneway ANOVA analysis was used to control residual 
somatic symptoms in relation to treatment response. Mean scores of residual 
somatic symptoms were higher for responders than remitters and even higher for 
non-responders, indicating worse treatment response in patients with more residual 
somatic symptoms. 
Finally, two separate regression models were constructed with total SF-36 quality of 
life after therapy as the dependent variable, and demographics and the most 
important pre- and posttreatment variables as the independent ones. Interpreting 
the results, the strongest influence on SF-36 health related quality of life outcome 
had the patients´ FLZ measured life satisfaction, the age, the diseased years, and the 
gender. A moderate increase in the side-effect burden of pharmacotherapy did not 
seem to impact significantly on HRQol outcome. It has to be noted, however, that 
  
 
4 1. SUMMARY 
many of the adverse effects that were attributed to psychopharmaca might not be 
true, as they overlap to some extend with the psychic, cognitive and affective 
features of depression. On the other hand, inpatients tend to attribute more adverse 
effects burden to their medication and perceive more often somatic symptoms as a 
part of the pharmacotherapy induced impairments. 
Summarizing, inpatient treatment was found to have a favourable effect on 
depression severity, health related quality of life, somatic manifestations and global 
functioning. Besides the core depressive symptoms, depression-related somatic 
manifestations play a significant, but rather complex role in treatment outcome. Our 
findings imply that targeting a higher drop in the somatic symptom scoring could be 
helpful in the reduction of depression severity. In addition, painful somatic 
symptoms are strongly associated with a worse treatment response. Finally, residual 
somatic symptoms, painful and non-painful, significantly enhance the side-effect 
burden and the depression severity posttreatment, and are related to further quality 
of life impairments.   
 
Conclusively, the acute inpatient treatment for depression could be considered 
beneficial for the patients and the pharmacotherapy good tolerated. When somatic 
symptoms accompany the already debilitating disease of depression, they should be 
recognized, targeted and treated to remission, parallel with the other depressive 
symptoms, in order to achieve an optimal clinical result. Such an approach may 
improve the inpatient care, reduce health costs and enhance patient´s and clinician´s 
satisfaction. Of course, future research on this field could further clarify the factors 
that might influence treatment outcome in a major depressive episode and be, 
therefore, potentially helpful in patient management in the future. 
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2. THEORETICAL BACKGROUND 
2.1. EPIDEMIOLOGY AND BURDEN OF DEPRESSION 
Major depression is ranked among the most common, disabling disorders and it is 
one of the major health threats of the 21th century (Liu, Wang et al. 1997), affecting 
each year about 340 million people worldwide (Greden 2003). Its negative 
consequences are described in terms of disability, secondary morbidity and 
increased mortality (Ebmeier, Donaghey et al. 2006). According to World Health 
Organization (WHO), major depression was considered as the fourth leading cause of 
global disease burden in 1990s (Ustun, Ayuso-Mateos et al. 2004) and is expected to 
be the second most common cause of disability by the year 2020 (Murray and Lopez 
1997). Recent projections for the years 2030 regard also major depression as one of 
the three leading disabling disorders, besides AIDS and ischemic heart disease 
(Mathers and Loncar 2006).   
Given its high prevalence rates, major depression was characterized as the “common 
cold of psychiatry” (Gilbert 1992; Goodwin 2008). A 12-month period prevalence of 
6.7% (Kessler, Chiu et al. 2005) and a lifetime prevalence varying between 17% and 
21% (Kessler, Berglund et al. 2005) were estimated according to DSM-IV criteria for 
Major Depressive Disorder (MDD). The point prevalence rate of MDD is 2% to 3% for 
men and 5% to 9% for women (APA 2000), manifesting that the disorder is 
experienced by females at least twice as often as by males, while the greatest 
incidence appears in the young and most productive ages, between 20 and 40 years 
(Kennedy 2007). In the medically ill population MDD prevalence is considerably 
higher, coming up to 10%-36% for general medical inpatients and 9%-16% for 
outpatients. 
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The occurrence of MDD has been associated with other serious mental or physical 
co-morbid disorders (Levenson 2005). The most common of the psychiatric co-
morbidities are anxiety disorders, substance abuse disorders and impulse control 
disorders (Kessler, Berglund et al. 2003). There is, furthermore, a strong interplay 
between major depression and physical illness. Physically ill patients are more 
susceptible to depression. Conversely, major depression may provoke or precipitate 
serious illnesses, such as cardiovascular diseases (Thomas, Kalaria et al. 2004; 
Ladwig, Emeny et al. 2011), cancer (Keller, Rigardetto et al. 2008), and epilepsy 
(Kanner 2009).  
For the individual, MDD is a serious condition leading to psychosocial dysfunction 
(Judd, Akiskal et al. 2000), decrease in quality of life (Isacson, Bingefors et al. 2005) 
and increase of mortality (Cuijpers and Smit 2002), mainly due to suicidality. Suicidal 
behaviour is particularly dependent on one specific facet of depression – feelings of 
hopelessness about the future and lack of positive thoughts. Depression is very 
common among those committing or attempting suicide (McLeod 2004). Conversely, 
it is estimated that about 10% to 15% of people suffering from major depression 
eventually commit suicide (Moller 2003).  
For the vast majority of patients, major depression is a chronic, frequently recurring 
illness. Data from the National Institute of Mental Health (NIMH) Collaborative 
Depression Study demonstrated impressively high recurrence rates, up to 60% in 5-
years and 75% in 10 years (Schatzberg 2009). The female sex, a lengthy index 
episode, prior depression episodes and non-experience of marital status have been 
suggested as the main risk factors for recurrence (Mueller, Leon et al. 1999).  
MDD has, besides its medical and social effects, also economic costs for the society. 
The high economic burden of major depression, which is related both to direct costs 
of increased health services utilization (Chen, Kales et al. 2007), and indirect costs 
because of the impaired work capacity of depressed subjects and subsequent loss of 
productivity, has been suggested to exceed the costs of an effective treatment 
(Wang, Beck et al. 2004). 
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2.2. HISTORICAL BACKGROUND 
In a comprehensive historical review, depressive disorders have been reported since 
the origins of medicine in ancient Greece. Hippocrates (460-337 BC) in his 23
rd
 
Aphorism defined depression as an excessively prolonged state of sadness. He used 
the term “melancholia” to describe the “black mood”, since it was attributed to 
excessive “black bile” (melan chole in Greek) in the brain. In the 2
nd
 century A.D., 
Rufus of Ephesus described persons who suffered from melancholia, as sad, gloomy, 
and fearful, with delusional ideas, involving guilt and sin. In the same period, Galan 
restated Hippocrates’ description of melancholia, as consisting of affective and self-
depreciative feelings, as well as somatic symptoms. That concept prevailed until the 
19
th
 century. In the English literature of the 18
th
 and 19
th
 century, there were for the 
first time observed occasional references of the term “depression”, originating from 
the Latin deprimere, which means to ‘press down’. Eventually, Emil Kraeplin (1887) 
distinguished between melancholia, which he considered as a type of insanity, and 
depression, which he regarded as a negative dysphoric mood or affect. Despite the 
introduction of Kraepelinian differentiation and nosology, subsequent ambiguity in 
the definition of depression emerged from differences in the emphasis on 
depression as a state of lowered mood that varies in intensity and the diagnosis of 
depression as a psychiatric disorder. As a part of this confusion, various methods 
have been used to identify the various subtypes of depression and their natural 
boundaries (Gilbert 1992).   
Today, in clinical use, the term depression is used to describe a cluster of symptoms 
involving significant changes in mood, in thinking and in activity. These symptoms 
persist and result in changes in personal and social functioning over a period of at 
least 2 weeks.  
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2.3. DIAGNOSTIC CRITERIA AND CLASSIFICATION OF SEVERITY OF 
DEPRESSION 
Since the introduction of the International Classification of Diseases and Causes of 
Death (ICD) and the Diagnostic and Statistical Manual of Mental Disorders, of the 
American Psychiatric Association (DSM) in the 1960s, an international systematic 
effort to develop a unified system of diagnosis and classification of depression and 
generally of mental disorders has started. The criteria for the diagnosis of depression 
have always emphasized negative, affective feelings and self-depreciating cognitions. 
Extensive field trials and multiple revisions have led finally to the latest symptom-
based classification systems ICD-10 (WHO 1993) and the compatible DSM-IV-TR 
Edition (APA 2000). Both of the current diagnostic classification systems, although 
they present some differences in specificity, are considered equal in validity and 
show no significant differences in diagnostic accuracy (Salloun I.M 2009). 
According to the ICD-10 Classification system, affective disorders are divided in five 
main categories: 1) bipolar depression or manic-depressive psychosis, with both 
manic and depressive episodes, 2) unipolar or major depression, without manic 
features, 3) recurrent depression, 4) persistent affective disorder (cyclothymia, 
dysthymia) and, 5) other mood disorders (specified-unspecified).  
Diagnosis of MDD is based on anamnestic information and observation of clinical 
symptoms, not on evidence of underlying neurobiological pathology. The symptom-
based criteria for the diagnosis of major depression, following the ICD-10 
Classification, is based upon the combination of three typical symptoms, such as 
depressed mood, loss of interest and psychomotor retardation, and other usual 
ones, such as weight or appetite loss, sleep disturbance, morbid or suicidal thinking, 
feelings of worthlessness or restlessness (Table 1a, annex).  
The severity of symptoms in depression is a key dimension (Goethe, Fischer et al. 
1993). According to ICD-10, major depression is graded, depending upon the number 
and severity of symptoms, as mild (F32.0), moderate (F32.1) and severe (F32.2 and 
F32.3). For each category, at least two typical symptoms are required with the 
presence of at least two of the other usual ones for mild and at least four for severe 
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depression. Recurrent episodes are also classified according to severity in mild 
(F33.0), moderate (F33.1) and severe ones (F33.2 and F33.3). A duration of at least 2 
weeks is required for diagnosis, but shorter periods may be reasonable if symptoms 
are unusually severe or of rapid onset.  
In a similar way the DSM-IV-TR classification requires for the diagnosis of major 
depression a minimum 2-week period of symptomatology and at least five out of 
nine symptoms that result in significant distress or impairment in social, 
occupational or other important areas of daily functioning (Table 1b, annex). One of 
the symptoms has to be either depressed mood or lost of interest or pleasure, in 
order to set a diagnosis. DSM-IV-TR also categorizes major depressive episodes as 
mild, moderate and severe according to the severity of symptoms.  
2.4. SOMATIC SYMPTOMS IN DEPRESSION 
The major depressive syndrome, besides its cognitive and affective components, has 
also somatic manifestations. There is substantial literature demonstrating a strong 
association of somatic symptoms with major depression (Katon, Kleinman et al. 
1982; Kroenke, Spitzer et al. 1994; Simon, VonKorff et al. 1999; Gulec, Sayar et al. 
2005). Somatic symptoms are prevalent in a great majority of patients suffering from 
depression (Nelson and Charney 1981; Hamilton 1989), so that they are described as 
a core component of it (Simon, VonKorff et al. 1999). It is estimated that at least 50% 
of the depressed patients in primary care present with predominantly somatic 
complaints rather than cognitive or affective depressive symptoms (Gureje and 
Simon 1999).  
Historically, somatization was defined by Steckel as a deep-seated neurosis that 
produced bodily symptoms. In the recent years, the term somatization has been 
used to describe the tendency of certain patients to experience and communicate 
somatic distress in response to psychosocial stress and to seek medical help for it 
(Lipowski 1988). Katon pointed out the intricate relationship between major 
depression and somatization, describing the latter as the selective perception and 
focus on the somatic manifestations of depression with denial or minimization of the 
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affective and cognitive changes (Katon, Kleinman et al. 1982). The term somatization 
in depression was further used to describe the tendency of patients to experience 
numerous physical symptoms for which no apparent organic cause can be 
determined and that do not result from the direct effect of drug abuse or medication 
(Maj 2002). Alternatively, if a medical cause exists, somatization is considered to be 
present when complaints about the bodily disturbance and dysfunction are in excess 
of the pathology (APA 2000).  
In medical literature, a redundancy of terms is used to describe the somatic 
symptoms in depression, such as physical symptoms, painful physical conditions, 
medically unexplained symptoms, functional somatic symptoms, somatization, 
somatised complaints, somatoform or psychosomatic symptoms, and masked 
depression or depressive equivalents. However, somatic symptoms in depression 
should not be confused with hypochondriasis or somatoform disorders, which are 
more severe chronic disorders, predisposing strict diagnostic criteria. The former is 
mainly characterized by preoccupation of the patient with fears of having a serious 
disease, based on misinterpretation of his bodily symptoms. The latter (historically 
referred to as hysteria or Briquet´s syndrome) has an early onset (before 30), 
extends over a period of years and predisposes a combination of pain, 
gastrointestinal, sexual, and pseudoneurological symptoms (APA 2000).   
Various mechanisms may contribute to the presentation of depression with somatic 
symptoms, including sensitization of the brain to bodily sensations (Pyne, Patterson 
et al. 1997), physiological abnormalities in the nervous and endocrine systems (Maj 
2002), heightened awareness of bodily sensations (Kroenke, Spitzer et al. 1994), 
somatosensory amplification (Spinhoven and van der Does 1997) and inappropriate 
illness beliefs and sickness behaviour (Kirmayer, Robbins et al. 1993). Experiencing 
one or just a few medically unexplained symptoms (e.g. dizziness or upset stomach) 
is common in "normal" people under social or emotional distress (Simon, VonKorff et 
al. 1999). However, experiencing many unexplained symptoms from different organ 
systems (e.g. dizziness and upset stomach and palpitations and muscular aches) 
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implies the existence of somatizing as described above (Kirmayer, Robbins et al. 
1993).  
Among bodily symptoms, special consideration should be given at painful ones, 
which are currently listed in DSM-IV-TR as an ``associate feature´´ of MDD. Painful 
symptoms are responsible for over 50% of the medical visits due to somatizing and 
are present in more than 50% of the depressed patients (Kroenke 2003). Pain is also 
mentioned as a risk factor for poor antidepressant therapy response (Kroenke, West 
et al. 2001). Furthermore, the worse the painful somatic symptoms are presented, 
the more severe and the longer a depressive episode persists (Kapfhammer 2006). 
Most likely to present with somatic symptoms are depressed patients who lack 
psychological insight, are reluctant or unable to express their emotions verbally, are 
elderly, poorly educated and feel ashamed to acknowledge psychological problems 
(Kapfhammer 2006). Furthermore, gender differences are also reported, with 
females presenting more often with somatic symptoms than males (Kapfhammer 
2007). Severe early trauma, culture and society, as well as type of patient-physician 
relationship are further factors contributing to the presentation of a depressive 
mood in a predominantly somatic way. Depending on the individual patients’ 
characteristics and their social and cultural backgrounds, the symptoms may also 
vary in number and type, but commonly include bodily diffuse pains, muscular 
tension, fatigue as well as gastrointestinal disturbances. All symptoms are usually 
vague, unstable und inexplicable by the results of the physical and laboratory 
controls. 
Somatic symptoms have been described as strong clinical predictors of underlying 
depression (Kroenke, Jackson et al. 1997; Hotopf, Mayou et al. 1998; Nakao and 
Yano 2003) and as the most common clinical presentation of depressed patients in 
medical settings around the world (Simon, VonKorff et al. 1999). About 80% of 
depressed subjects present their depressed mood exclusively with physical 
symptoms (Kirmayer, Robbins et al. 1993), which is presumed to contribute to the 
underrecognition of the underlying, “masked” depression (Kirmayer, Robbins et al. 
1993) and subsequently to an inadequate therapeutical approach. Indeed, primary 
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care physicians fail to diagnose at least 50% of patients with major depression (Katon 
and Sullivan 1990). Patients with medically unexplained physical symptoms account 
for 15-30% of all primary care consultations (Kirmayer, Groleau et al. 2004), while 
the prevalence rate of major depression among such patients comes up to 50% 
(Greco, Eckert et al. 2004). That group of patients tend to rely heavily on medical 
services (Tylee and Gandhi 2005), since they suffer from various symptoms from 
time to time, raising significantly the health cost for the community, as well as the 
economic burden for them and their employers (Greenberg, Leong et al. 2003).  
In the case of major depression, and generally affective disorders, the early 
recognition and diagnosis are of crucial importance. From a diagnostic perspective, 
one has to keep in mind that bodily symptoms play a significant role in psychiatric 
disorders. It has been argued that medically unexplained bodily symptoms are a 
manifestation of an affective-spectrum disorder (Hudson, Mangweth et al. 2003), 
and the vast majority of such cases concern depression (Katon, Kleinman et al. 
1982). Consequently, in differential diagnosis, somatic symptoms should be 
considered as indicative of underlying mood disorders and be assessed in line with 
typical comorbid affective, behavioural and cognitive symptoms of depression.  
2.5. QUALITY OF LIFE AND DEPRESSION 
The term “quality of life’’ (Qol) made its appearance for the first time in the 1950s 
and was used roughly as a synonym for the “standard of living”, having mainly 
socioeconomic determinants. Many other definitions of “quality of life” have been 
attempted since then, often emphasizing on happiness and life satisfaction or linking 
it with “health”, while is still no consensus as to what constitutes Qol. Although most 
people are nowadays familiar in conceptualizing the term “quality of life”, there is 
still no globally accepted definition. The World Health Organization (WHO) defined 
‘‘quality of life’’ as ‘‘an individual’s perception of their position in life in the context 
of the culture and value systems in which they live, and in relation to their goals, 
expectations, standards and concerns’’. That generic conceptualization of Qol can be 
distinguished from the more specific concept of “health-related quality of life” 
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(HRQol), which refers to all those aspects of one’s life that impact directly upon their 
health status.  
As regarded in the literature, it has a rather imprecise multidimensional concept. 
From a more scientific point of view (Angermeyer 1997), it encompasses mainly 
three aspects: a) life satisfaction or subjective well-being, b) social functioning and c) 
access to environmental resources, social and physical. The outcome of quality of life 
is considered as the result of the interplay between all those three components.  
In clinical practice, all domains of quality of life are significantly influenced by 
depression. This complex, multifaceted mood disorder leads to multiple Qol 
decrements (Hays, Wells et al. 1995; Barge-Schaapveld, Nicolson et al. 1999) in the 
lives of the affected subjects. Even moderate depression erodes one’s ability to 
handle everyday responsibilities, to enjoy life, to express affection and to consider 
oneself worthwhile (Ingram 2009). Feelings such as helplessness and hopelessness 
are often excruciatingly present during a major depressive episode. It is not 
surprising, then, that most cases of suicide are the result of severe depressive states. 
Depressed patients present with significant distress or impairment in social, 
occupational and other important areas of daily functioning, when compared to both 
symptom- negative or positive non-depressed persons (Lonnqvist, Sintonen et al. 
1994; Spitzer, Williams et al. 1994; APA 2000). The stigma of mental illness has 
additionally been blamed for the poor individual medical and social outcomes 
surrounding depression (Pescosolido 2007). Qol in depressive states is even lower 
than in serious physical illness, such as diabetes or arthritis (Wells, Stewart et al. 
1989). Comorbid depression in medical illness increases further the burden of 
functional impairment and treatment of depression diminishes both dysfunction and 
health service costs (Simon 2003). The statement that “there is no medical disorder, 
which can impair the quality of life more than depression” (Maj 2002) might be, after 
all, to some extent justified. 
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2.6. MEASURING HEALTH-RELATED QUALITY OF LIFE IN DEPRESSION 
One of the most useful and promising applications of the quality of life concept 
nowadays is for measuring health outcomes. Measurement of “health related quality 
of life’’ (HRQol) has grown to become a standard endpoint in many clinical studies 
and randomized control trials. It seems that in the contemporary health care 
environment, which precisely estimates on costs and outcomes, the concept of 
HRQol has a large integrative potential. Clinicians and policymakers are increasingly 
recognizing the importance of measuring HRQol to inform patient management and 
policy decisions (Guyatt, Feeny et al. 1993). Various reviews have given valuable 
insight into the potential wider reaching impact of psychotherapeutic intervention 
and importance of including, besides symptom reduction, HRQL as an outcome in 
clinical practice (Berlim, Fleck et al. 2008; Swan, Watson et al. 2009). It has been 
suggested that Qol instruments can provide levels of information not always 
supplied by traditional outcome measures (Michalak, Yatham et al. 2005).    
In modern Psychopathology, there is also accumulating evidence that mental health 
should be described in broader concepts, than just in terms of elimination of disease 
specific symptoms, including dimensions such as health-related quality of life 
(HRQol), life satisfaction, role functioning, social irritability and interpersonal 
interaction. As far as depressed patients are concerned, it is increasingly recognized 
that the symptoms of depression, either somatic or non-somatic, are powerful 
predictors of health-related quality of life (HRQol) (Lenz and Demal 2000; Koch, van 
Bokhoven et al. 2007; Gunther, Roick et al. 2008; Hyphantis, Tomenson et al. 2009). 
And although depression is negatively associated with HRQol, diagnostic specific 
symptoms of the mental disorder can explain only a small proportion of variance in 
quality of life (Strine, Kroenke et al. 2009), implying the need for multifactorial, 
research approaches.  
Adversely, changes in the Qol are not solely an epiphenomenon of the mood state, 
and from that point of view are not redundant measurements, as it was previously 
reported (Katsching 1990, Schwarz and Clore 1983). Since then, several reviews and 
pharmacotherapeutic depression trials revealed that Qol measures could be 
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sensitive to treatment change, independent of the actual current affective state 
(Michalak, Yatham et al. 2005; Swan, Watson et al. 2009). Therefore, including 
measurements of HRQol, self-perceived health and global functioning in current 
research of depression provides a way to assess the effectiveness of new and 
existing therapies, beyond their ability to relieve disease-specific symptoms, as well 
as a basis for planning more effective treatment approaches (Barge-Schaapveld, 
Nicolson et al. 1999). 
The first questionnaires for assessing QOL, such as the Konovsky-, the Spitzer-, the 
Grogonow- and the Rosser-Index were one-dimensional. The growing societal and 
scientific demand for more holistic, objective and precise assessment of QOL has led 
to the development of the multidimensional measuring instruments of the second 
generation, which include all of the three basic aspects of well-being: physical, social 
and psychic.  
Qol instruments are generally separated in two categories, those measuring domain-
specific Qol, such as satisfaction with one’s health, and those measuring a global 
feeling of satisfaction. The latter can be evaluated either by measuring a single item 
or by combining scores on various domains (McAlinden and Oei 2006).  
There are also generic and specific instruments, subjective and objective 
approaches, measures of positive and negative aspects of Qol.  Some of the most 
widely used questionnaires are the Short-Form 36 (SF-36), the FLZ (Fragen zur 
Lebenszufriedenheit) Questionnaire, the Lancashire Quality of Life Profile (LQLP), the 
Quality of Life Questionnaire (LQF) and the Nottingham Health Profile (NHP). In the 
current study measures of both objective and subjective HRQol were conducted by 
using the first two of the prementioned instruments. Their description follows in 
next sections.  
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2.7. RATING SCALES IN DEPRESSION  
Although rating scales were almost exclusively used in research settings in the past, 
our better understanding of their benefits has led them to become more and more a 
standard part of the clinical delivery of care. Their broader use by clinicians into 
routine clinical practice was enhanced by several studies, such as STAR*D (Rush, 
Trivedi et al. 2006) und STEP-BD (Perlis, Ostacher et al. 2006), which showed that 
rating instruments help to construct real therapy effects similar to those of efficacy 
studies. By implementing measurement-based care, clinicians can screen patients 
with a systematic method for key disease symptoms and also identify possible 
``hidden´´ comorbidities, determine the effectiveness of treatment, and also link 
their work to the growing empirical literature. 
The most commonly used rating scales in depression are the following (Cusin 2010): 
• The Hamilton Depression Rating scale (HAMD), a clinician-rated scale, which 
was introduced in the late 1950s to evaluate the effectiveness of the first 
antidepressants. Since then, it has become the gold standard for measuring 
depression severity. It is considered as the most widely used scale in clinical trials of 
antidepressants (Ryder 2005) and the most frequently used instrument among 
naturalistic designs (Bland 1997). 
Although the original version included 21 items, the 17-item version is the most 
commonly used, since the last 4 items (diurnal variation, 
depersonalization/derealization, paranoid symptoms, and obsessive-compulsive 
symptoms) are either very infrequently or  do not measure depression severity 
(Hamilton 1960).  
HAMD-17 scale was used at baseline and at discharge in the current study, as an 
instrument to evaluate severity of depression, somatic symptoms and existence of 
pain in the sample population, as well as screen for response and remission to the 
treatment. 
• The Beck Depression Inventory (BDI), which is the gold standard of self-rating 
scales. It was initially designed to assess the effectiveness of psychotherapy in 
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depression. The measurement reflects the severity of depressive symptoms that are 
currently experienced by the test taker.  
• The Inventory of Depressive Symptomatology (IDS), which was developed in 
the 1980s. It is a clinician-rated index, including all the symptom fields of the DSM-
based major depressive disorder, as well as melancholic and atypical features.  
• The Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated 
10-item scale, which was designed to assess the effects of antidepressants. It is a 
one-dimensional scale, focused rather on psychological than somatic aspects of 
depression.  
• The Zung Self-Rating Depression Scale, which is a 20-item self-rated index, 
including a broader spectrum of depression symptoms, such as psychic, affective, 
behavioral, cognitive and somatic. 
2.8. TREATMENT OF DEPRESSION 
The main goal of depression treatment is symptom remission or full response 
(Zajecka 2003; Rush, Kraemer et al. 2006), defined as a complete resolution of 
symptoms and restore of the premorbid baseline social and occupational function, 
as well as prevent of relapse or recurrence (Kennedy 2007; Trivedi 2009).  
Despite the use of new, innovative antidepressants in recent decades, major 
depression remains a common and very often inadequately treated illness. It is 
estimated that fewer than 25% of those affected finally receive an effective 
treatment. In case of unsatisfactory outcomes, despite of an optimally delivered 
treatment, a resistance to treatment is said to occur (Tyner 2008).  
Whereas an untreated episode of depression may persist for 6 to 13 months, treated 
episodes last in average 3 months (Alladin 2007). Approximately one third of the 
treated patients achieve full remission (Shiloh 2006), whereas in 20-35% there is a 
chronic course of the disease associated with considerable residual symptoms and 
social impairment (APA 2000). In addition, depressive symptoms themselves may 
lead to poor compliance with therapy (Clarke and Goosen 2005) and subsequently to 
higher rates of relapse. In general, in the presence of more intense symptoms and 
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painful somatic manifestations, the depressive episode is more severe and persistent 
(Kapfhammer 2006) and the therapeutical response less favourable to expect  
(Greenberg, Leong et al. 2003).  
The treatment of depression consists mainly of three phases, the acute, the medium-
term and the long-term therapy. The acute treatment of a major depressive episode 
lasts typically 6-8 weeks; thereby response can normally be expected after 4 weeks 
and full remission after 8 weeks. The medium-term therapy typically lasts 6-12 
months and is called relapse-prevention or continuation therapy. The long-term 
therapy is prophylactic and serves to prevent the recurrence of new episodes of 
major depression. Suicide risk should be regularly assessed throughout the course of 
therapy. Patients who show a high suicidal risk or refuse food and drink or non 
responders to the outpatient therapy require hospital admission, which may be 
conducted in some cases even involuntarily (Gill 2007). 
In the treatment of major depression both pharmacotherapy and psychotherapy 
have been shown effective (Antonuccio, Danton et al. 1999; Schulberg, Katon et al. 
1999). Results of the University of Minnesota Study of Cognitive Therapy and 
Pharmacotherapy supported no superiority of either of the two therapies separately 
(Hollon, DeRubeis et al. 1992). Their combination, however, has been associated 
with better measure outcomes in the treatment of chronic and severe depression, 
than each modality alone (Thase, Greenhouse et al. 1997; Keller 2000).  
• PHARMACOTHERAPY IN DEPRESSION AND ITS SIDE EFFECTS 
The diagnosis of major depression is considered as the main indication for an 
antidepressive pharmacotherapy. Pharmacotherapy of depression is based on the 
premise that this condition is associated with a deficit in various neurotransmitters 
known as monoamines, such as noradrenalin, serotonin, and dopamine. Medication 
affect these neurotransmitter systems in different combinations and to varying 
degrees (Ebmeier 2003). Overall, 50% to 65% of patients can be expected to respond 
to any given trial of an antidepressant medication (Schatzberg 2005).  
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The use of “antidepressants” was introduced in the early 1960s. The antidepressants 
of the first generation can be classified to those based on the structure of the tricycle 
imipramine (TCAs) and to monoamino-oxidase inhibitors (MAOIs). In the 1980s, 
there have been introduced the antidepressants of the second generation, such as 
the selective noradrenalin reuptake inhibitors-(NARIs) and the selective serotonin 
reuptake inhibitors (SSRIs).   
Several reviews and meta-analyses of randomized, double-blind antidepressant 
studies have shown higher effectiveness of antidepressants versus placebo (Song, 
Freemantle et al. 1993; Joffe, Sokolov et al. 1996; Arroll, Macgillivray et al. 2005). 
Pharmacoeconomic evaluations in randomized, controlled trials have given no 
evidence that any one group of antidepressants provides more cost-effective 
treatment than another group (Donoghue 2002; Hansen, Gartlehner et al. 2005). 
Today, there are many antidepressants available, which can be classified in three 
pharmacological classes:  
1. The irreversible MAO (mitochondrial monoamine oxidase) type A and B 
inhibitors (MAOIs: tranylcypromine), and the reversible MAO type A inhibitors 
(RIMAs: moclobemide). MAO type A is the main enzyme of serotonin and 
norepinephrine metabolism, while type B of dopamine metabolism.   
2. The reuptake blockers, such as the tricyclic antidepressants (TCAs), the SSRIs 
(fluoxetine, sertraline, citalopram, escitalopram), the serotonin and 
norepinephrine reuptake-blockers (SNRIs; duloxetine, venlafaxine, milnacipran) 
and the norepinephrine and dopamine reuptake inhibitor (bupropion). 
3. The pre- and postsynaptic receptor blockes, such as mianserin, nefazodone, 
trazodone and mirtazapine.  
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A general classification of the antidepressant agents according to mechanism of 
action is shown in the following figure. 
Figure 1. Classification of antidepressants 
Practically, all antidepressants increase the monoamine concentration in the 
synaptic cleft. A chain of intra- and intercellular events following antidepressant 
administration take place and they lead to the resolution of depression, which 
usually takes about 4-8 weeks to be achieved (Shiloh 2006).  
Besides antidepressants, pharmacotherapy for major depression may also include 
other psychotropic substances, such as tranquillisers, hypnotics, neuroleptics and 
lithium. In clinical practice, combinations of antidepressants with other psychotropic 
substances acting as augmentation agents, such as antipsychotics, thyroid hormone, 
mood stabilizers and anxiolytics, are very common. 
Regarding the outcome of pharmacotherapy, with reference to HAMD-17, a 
response is usually defined as at least 50% reduction of the pre-treatment score, and 
a full remission as a score of 6 or less (Riedel, Moller et al.). Although 
antidepressants are very effective, since 75% of the patients show a favourable 
response, only to one third of them can a full remission be achieved (Shiloh 2006).  
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Despite the different neurochemical actions, most systematic reviews have not 
revealed clinical significant differences in response rates among the various 
antidepressants, either of the first or second generation (Elkin, Shea et al. 1989; 
Williams, Mulrow et al. 2000; Kennedy 2007), at least in the short treatment of 
major depression, while their comparative evaluation in the medium- and long-term 
therapy have been rather limited evaluated (Weilburg 2004).  
Despite their comparable efficacy, antidepressants have shown different side effect 
profiles. Subsequently, besides the potential for benefit, the nature and severity of 
adverse drug reactions play a significant role in treatment decisions (Loke and Derry 
2001). Selectively using some adverse reactions as desired outcome could improve 
adherence. A recent review (Bostwick 2010) proposes that physicians, once they 
decide to prescribe antidepressants, should use side effects to advantage, by 
selecting medications to minimize negative and maximize positive possibilities. For 
example, sedation or weight gain as side-effect could lead to individually desired 
longer sleep or improved appetite. Nevertheless, it is sometimes underestimated 
how annoying and distressing, even some of the “minor” side-effects can be. The 
wider use of the newer antidepressants, such as SSRIs, could be generally attributed 
to the lower rates of side effects (McGillivray, 2003) and their better tolerance. 
Although adverse reactions of antidepressants are dose-dependent, they can be 
observed, even at therapeutic levels (McElroy, Keck et al. 1995). The most serious 
and emergent condition is suicidality. The association of antidepressants and suicide 
risk is rather ambiguous. Although some trials showed no evidence, or at least no 
conclusive one, that antidepressant drugs increase or decrease suicide risk, when 
compared to placebo treatment (Selvaraj, Veeravalli et al. ; Khan, Khan et al. 2001), a 
meta-analysis of 372 double blind randomised placebo controlled trials (Stone, 
Laughren et al. 2009) showed a strongly-age dependent risk of suicide associated 
with use of antidepressants. In psychiatric care settings, however, where 
assessments of suicidality by trained psychiatrists are daily conducted, this risk might 
be overweighed by the improvement and the in-patient treatment might be 
beneficial (Seemuller, Riedel et al. 2009).  
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As far as the less serious but more common side-effects of antidepressants are 
concerned, they may include anticholinergic effects, such as blurred vision, dry 
mouth, urinary retention, constipation or diarrhoea, nausea and delirium, or 
sedative effects, speech and cognitive deficits, excessive perspiration and weight 
gain or loss. Depending on the dose and type of the antidepressant, there has been 
evidence of extrapyramidal symptoms, sleep disturbances, mania and seizures. The 
cardiovascular symptoms associated with antidepressive medication include hypo- 
or hypertension, heart failure, arrhythmias and very seldom sudden death. Sexual 
side-effects may also be present, involving more often decreased libido, erectile 
dysfunction and ejaculatory impairment. The most common side-effects are shown 
in figure 2 (Kennedy 2007). 
 
Figure 2. Side effects of antidepressants 
Since side-effects and lack of efficacy are the main causes for pharmacotherapy 
discontinuation in 30% to 60% of the cases, irrespectively with the type of the 
administered antidepressant (Anderson and Tomenson 1995; Menting, Honig et al. 
1996), the evaluation and management of adverse reactions should be an important 
part of the therapeutic plan.   
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It should be noted at this point that the side effect assessment comes up against the 
difficulty of distinguishing between somatic symptoms caused by depression and 
those caused by treatment (Gruwez, Gury et al. 2004). Many of the antidepressant 
adverse reactions may resemble the symptoms of major depression. In addition, 
major depression includes symptoms that may be interpreted as side-effects of the 
medication (Balon 1999). For example, headache, constipation and drowsiness –
symptoms usually considered as side effects- have been observed in more than 50% 
of untreated in-patients with major depression if these symptoms were each directly 
assessed (Nelson 1984). During treatment patients may be quick to label these 
somatic symptoms as side effects, even if the symptoms were pre-existing. Another 
manifestation of this issue is the rate of spontaneously reported side effects on 
placebo in clinical trials. For example, clinical trial data for recently marketed 
antidepressants indicate that the rate of headaches on placebo in depressed 
outpatients ranges from 17-24% (Schatzberg F.A 2009). A strong argument could be 
made that headache is a common somatic symptom of depression. Of course, 
important factors contributing to side effects are also the patient’s vulnerability and 
general medical condition.  
Conclusively, the final manifestation of somatic symptoms during treatment is the 
net result of the interaction of direct effect of medication on specific organs, the 
indirect medication effects on depression and its associated somatic symptoms, and 
the patient’s vulnerability to certain symptoms. The attribution of cause–that is 
whether a physical symptom is side effect of a drug or a symptom of depression – 
involves a judgment about whether the symptom is new or has worsened during 
drug treatment.    
The effort to make the side effect evaluation more objective and quantifiable has led 
to the development of several measure scales, such as the Udvalg for Kliniske 
Undersogelser (UKU) Side Effect Rating Scale (Lingjaerde, Ahlfors et al. 1987; Jordan, 
Knight et al. 2004), which was used in the current study and is described in following 
section.  
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• PSYCHOTERAPY  
Psychotherapy is an alternative to drug treatment and includes cognitive therapy, 
behavioural therapy, cognitive behavioural therapy and inter-personal therapy. In 
some cases, it has been shown equally effective to pharmacotherapy, as far as mild 
to moderate types of depression are concerned (Barrett, Williams et al. 2001), or 
even more effective than pharmacotherapy alone (Steinbrueck, Maxwell et al. 1983; 
Dobson 1989). Moreover, during the acute episode, either combined with drugs or 
alone, it appears to reduce the subsequent relapse risk following treatment 
termination (Hollon, DeRubeis et al. 2005), decrease residual symptoms (Paykel, 
Scott et al. 2005) and may improve the long-term outcome in recurrent depression 
(Teasdale, Segal et al. 2000; Fava, Ruini et al. 2004). 
• OTHER TREATMENTS 
Electroconvulsive therapy (ECT), vagus nerve stimulation, deep brain stimulation 
(DBS), transcranial magnetic stimulation (TSM) or lesion based neurosurgery are 
neuromodulation techniques which, although at a preliminary phase of evaluation, 
have the potential to improve outcomes in specific target groups of patients. 
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3. PURPOSE OF THE STUDY 
Somatic symptoms are an integral part of depressive states. There is substantial 
literature to ascertain the significance of bodily symptoms, when they accompany 
depressive disorders, focusing mainly on their impact on the recognition and 
diagnosis of depression (Lipowski 1988; Kirmayer, Robbins et al. 1993; Allen, Gara et 
al. 2001; Kroenke 2003; Henningsen, Jakobsen et al. 2005; Tylee and Gandhi 2005; 
Chen, Hsu et al. 2007). However, increasing recognition of depression is only a first 
step toward a more appropriate treatment (Simon, Goldberg et al. 1999). The study 
of clinical measures and the exploration of therapy outcomes in all-day practice can 
provide valuable information about treatment effectiveness and promote the 
development of novel superior therapeutical approaches. The clinical significance of 
somatic complaints, regarding the treatment outcome, and their association with 
important secondary outcome measures, such as patients´ quality of life and life 
satisfaction, have been rather limited assessed. 
Under these considerations, the current naturalistic study aims to broaden our 
understanding for the role of somatic symptoms as regards the outcome of inpatient 
therapy for major depression, by exploring:   
• Significant correlations of somatic symptoms, painful and non-painful ones, 
with severity of depression, HRQol and life satisfaction measures, as well as side-
effect burden of pharmacotherapy, at baseline and at final visit. 
• The importance of the severity of somatic symptoms at baseline, by 
classifying the patients in mild and severe somatizers, as regards therapy outcome 
measures. Also, the impact specifically of painful physical symptoms at baseline on 
response and remission rates.  
• The residual somatic symptom scoring in relation to treatment outcome 
(remission, response, non-response). 
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• The independent influence of main demographic, disease history and pre- 
and posttreatment clinical variables on the outcome of SF-36 HRQol at the end of 
the acute phase therapy.   
• Finally, the hypothesis that the acute phase inpatient therapy for a major 
depressive episode is effective and good tolerated by the patients is assessed. 
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4. MATERIAL AND METHODS 
4.1. RESEARCH DESIGN 
The current study is a part of a large prospective, naturalistic, multicenter trial, 
which was conducted to explore issues such as treatment resistance, recurrence, 
chronicity and suicidality in inpatients treated for depression in the clinical settings 
of 7 psychiatric universities and 5 district hospitals. The project was funded by the 
German Federal Ministry of Education and research (BMBF), as part of the German 
research network on depression.  
The patients enrolled in the multicenter trial were biweekly assessed until discharge 
and then in one- and four-year follow-up. In the current study, outcomes of the 
acute treatment period for major depression are presented, based on data provided 
by applied clinical management tools at baseline and at discharge.  
4.2. SUBJECTS 
The study sample fulfilled the following inclusion criteria: 
1. Hospitalization with a first or recurrent major depressive episode of the 
diagnostic categories F32, F33, F34, F38, F39 according to the ICD-10 criteria, 
as a primary diagnosis. 
2. Age between 18 and 65 years. 
3. Signed written consent.  
From the study sample there were excluded patients with: 
1. Depression of organic origin. 
2. Bipolar depressive disorder. 
3. Insufficient knowledge of the German language. 
4. Residence place more than 100km far from the study centre.  
The diagnosis of major depressive disorder was also confirmed at baseline and at 
discharge according to DSM-IV, by means of the Structured Clinical Interview for 
DSM-IV (Wittchen 1997) , as well as according to ICD-10 criteria (WHO 1993) .  
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4.3. TREATMENT 
All subjects were treated in inpatient clinical settings, according to internationally 
established guidelines for the treatment of depression (American Psychiatric 
Association, (Blondiaux, Castro et al. 2000; Deutsche Gesellschaft für Psychiatrie 
2000) . They received: 
• Medication, including antidepressants, neuroleptics, tranquillizers, hypnotics, 
lithium and other psychopharmacologic compounds, as listed in Table 3 in the annex. 
The most frequently prescribed antidepressants in declining order were venlafaxine, 
mirtazapine, sertraline, citalopram, trimipramine, amitriptyline, reboxetine, 
doxepine, paroxetine and tranylcypromine. Lorazepame, diazepam und alprazopam 
were the most commonly used tranquillizers.  
• Other treatments non-pharmacologic, which are also listed in Table 3 in the 
annex. These were biological treatments, concerning ECT, sleep deprivation, light-
therapy, TMS. Some patients received also cognitive-behavioural therapy (CBT), 
physiotherapy, occupational therapy, and art and music therapy.  
The proportion in % of each of the administered pharmacological and non-
pharmacological therapies in the studied sample is also shown in Table 3 in the 
annex.  
4.4. ASSESSMENTS AND METHODS OF MEASUREMENT 
The administration schedule of instruments and outcome measures that were used 
in this study are listed in the 4
th
 Table below. 
 
Measure Pretreatment/ 
 at baseline 
Posttreatment/  
at discharge  
Demographics X  
HAMD X X 
SF-36 X X 
FLZ X X 
GAF X X 
UKU X X 
Table 4. Administration schedule of measuring instruments 
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The following assessments were conducted: 
Severity of depression and severity of somatic symptoms 
• The interview-based clinician-rated Hamilton Depression Rating Scale, 21 
items (HAMD-21) was used for the assessment of the severity of depression 
(Hamilton 1967), at baseline and at discharge.  HAMD has demonstrated reliability 
and concurrent and differential validity (Carroll, Fielding et al. 1973). Although the 
original HAMD version included 21 items, Hamilton pointed out that the last four 
ones (diurnal variation, depersonalization/derealisation, paranoid symptoms, and 
obsessive-compulsive symptoms) should not take part in the total score, since they 
are rather unusual and do not reflect depression severity. So, in the current study, 
outcomes referred to the HAMD-17, extracted from the original 21-item version. For 
the 17-item version, scores can range between 0 and 54. Patients with total scores 
under 7 at baseline were not included in the study, since such scores are not 
considered as indicative of depression by most clinicians. Patients with scores 
between 7 and 17 were considered as having mild depression, patients with scores 
between 18 and 24 as having moderate depression and patients with scores over 24 
as having severe depression (Cusin 2010) . 
The scores of the items 4, 5, 6, 11, 12, 13, 14, and 16 of the HAMD scale, which 
referred to bodily manifestations, were added separately for the evaluation of the 
severity of somatic symptoms. The item 13 was also assessed as a single score, 
depicting specifically the painful of the somatic symptoms. 
The main outcome criteria response and remission were also referred to HAMD-17. 
Response was defined as at least 50% reduction in the HAMD-17 baseline score. 
Remission was considered when HAMD-17 score at endpoint was equal or less than 
6 (Riedel, Moller et al.).  
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Subjective and objective quality of life 
• The Short-Form health survey questionnaire SF-36 (Ware and Sherbourne 
1992) is a 36-item scale designed to evaluate the level of functioning and quality of 
life variables, including general health perceptions, physical functioning, role 
limitations due to physical health problems, pain, social functioning, role limitations 
due to emotional problems and vitality.  The response options for the items on the 
SF-36 vary depending on the question. Some responses have a Likert scale format, 
with ranges varying from item to item, while other items are scored as 
absent/present. It yields an 8-subscale profile of functional health and well-being 
scores, as well as a physical and a mental major subscale (physical and mental 
component), as shown in Figure 3. Those 2 major subscales are obtained from the 8 
SF-36 subscales (Ware, Kosinski et al. 1995).  
 
Figure 3. SF-36 components and subscales 
The current version is a shorter one than the original that was developed for use in 
the Medical Outcomes Study (MOS). It was designed to be a generic instrument that 
can be used with multiple populations of varying ages and diseases (Ware 1996). It 
has proven useful in surveys of general and specific populations, comparing the 
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relative burden of diseases, and in differentiating the health benefits produced by a 
wide range of different treatments. 
Internal consistency and test-retest methods have been used to estimate the eight 
scales of the SF-36 and statistics on reliability have demonstrated at least 0.70 in 
group comparison studies (McHorney, Ware et al. 1993). Content validity has been 
demonstrated and comparison studies have identified the SF-36 as an accurate 
representation of health concepts that correlate with the intensity and rate of 
recurrence of many specific symptoms (r=0.40 or greater). Further, studies using 
physical and mental health criteria have demonstrated that the SF-36 has 80-90% 
empirical validity (McHorney, Ware et al. 1993).  
In the current study, the 2 major subscales of SF-36 for the physical and mental 
health, the 8 subscales of the SF-36 (physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional, mental health), as well as 
the total SF-36 scores, were estimated pre- and post-treatment, as described in the 
literature (Ware and Sherbourne 1992).  
The assignment of the various items to the construction of 8 subscales is shown in 
Table 5. 
           
Subscales  SF-36 
 
Sum scoring of the items 
(raw value) 
Possible 
lowest and 
highest raw 
values 
Possible 
range of 
raw 
value 
1. Physical functioning 3a, 3b,3c,3d,3e,3f,3g,3h,3i,3j 10-30 10-30 
2. Physical role functioning 4a,4b,4c,4d 4-8 4-8 
3. Physical pain 7**,8** 2-12 2-12 
4. General health 1**,11a,11b*,11c,11d* 5-25 5-25 
5. Vitality 9a*,9e*,9g,9i 4-24 4-24 
6. Social functioning                      6*,10  2-10  2-10 
7. Emotional role functioning 5a,5b,5c 3-6 3-6 
8. Psychological well-being 9b,9c,9d*,9f,9h*   5-30   5-30 
Table 5. The construction of SF-36 subscales 
Before adding the item scores on the scales there should be paid attention on 
particularities at values marked with star: 7 in direction of bad health polled items 
(*) are to invert, 3 items (**) will be recalibrated in order to preserve equidistant 
scale levels, while the encoding of the item 8 is dependent upon answering the item 
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7. Up to 50% missing values can be tolerated for each scale and replaced if necessary 
by the average scale value. 
In a further step, the different areas of standardized scales will be unified at the 
same span of 0-100, with a higher score indicating better function. The scales have 
been constructed, so that the population norm for each score is 50. According to the 
formula:  Y transformed scale= ((Y actual raw value - Y possible lowest value of the raw scale)/ Y 
possible range of the raw scale value) x 100, transformed scales can be interpreted as a 
percentage of the maximum value of each scale.  
The item 2, which concerns the change of health status, is separately valued and will 
not be transformed. The answers on this item can be analyzed as ordinal scaled data 
and the percentage of each possible answer can be separately estimated.  
To the construction of the raw values of the 2 major subscales, the mean scores, the 
standard deviations and regression coefficients have to be estimated for each one of 
the 8 subscales, based on the norm z-values. The raw values of the major subscales 
should finally also be transformed having a mean score equal to 50 (Bullinger 1998). 
 
• The FLZ (Fragen zur Lebenszufriedenheit) questionnaire for life satisfaction is 
a self-rating tool which, compared to other most common quality-measurement 
tools, brings the subjective assessment of functioning in various areas of life in the 
foreground.  
The development of the FLZ included several phases of data analysis with healthy 
and ill samples. Based on statistics and feedback data from respondents, the number 
and wording of the included items, the number and wording of the response 
categories, and subsequently the statistic formulas were in the past many times 
modified and optimized.  
The initial 16-item version of the FLZM module (Henrich G 2000), including 8 general 
dimensions and 8 health related items, was optimized for the assessment of the 
inpatients in the current study, by including additional items such as the medical 
therapy, the disease management, as well as parameters such as self-esteem, 
success and recognition. Other health related items, such as hearing and seeing, 
which were not expected to be influenced by the disease or the therapeutical 
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approaches on the depressed inpatients and subsequently were not considered as 
outcome parameters, were excluded. Moreover, family life was assessed alone, 
without the parameter of children, since many of patients had no children at all and 
this could influence the final scores in different ways. Finally, partner relationship 
and sexual life, which were considered as important parameters being influenced 
perhaps to a different extent by major depression and its therapy, were assessed not 
as a single item, as in the original version, but separately.  
So, finally 20 domains were evaluated according to 10-staged Likert scales, with 
possible answers varying between totally unsatisfied/ unimportant (=0) and very 
satisfied/important (=9). The values `satisfaction´ (Z) and `importance´ (W) were 
combined, so that a weighted satisfaction (gZ) was estimated for each domain 
separately, in line with the criteria of the classic test theory. To the construction of 
gZ, the values Z and M were multiplied, in a way that that: a) the first category `total 
unimportant´ resulted in gZ scores 0, b) the category `neither satisfied/nor 
unsatisfied´ also included the value 0. This category cames not explicit in the scale, 
but it lied at the value 5, so the value 5 had to be removed from the original value z. 
To attribute the stronger effect of Z values in comparison to W as regards the 
weighed satisfaction gZ, similarly to the earliest formula proposed by Henrich and 
Herschbach (Henrich 2000) , w values had to be halved. So, in the current statistical 
analysis, weighed satisfaction scores were produced using the relationship 
gZ=(W/2)*(Z-5), were Z was the mean score for each of the questions 1-20 and W 
was the mean score for each of the corresponding questions 21-40. Resulting scores 
ranged from -25 to 25. Higher scale scores indicated more satisfaction with the 
respective areas. 
 
• The Global Assessment of Functioning (GAF) Scale, a modified version of the 
Global Assessment Scale (GAS), first appeared in DSM-III-R in 1987. It is used 
according to the guidelines of DSM-IV (APA 2000), for reporting the clinician´s 
judgment of the individual´s overall level of functioning on Axis V.  
The GAF scale is to be rated with respect only to psychological, social and 
occupational functioning, without including impairments in functioning due to 
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physical or environmental limitations. It is based on the assumption that the level of 
current functioning in psychiatric populations holds crucial information for 
treatment planning and treatment outcome. It may be particularly useful when the 
clinical progress of a patient needs to be assessed in global terms, using a single 
measure. 
The GAF is similar to the GAS in that it has similar criteria and the same interval 
design, a value range from 0 (most severe) to 100 (least severe) with 10 anchor 
points at equal intervals (Hall 1995). The interpretation of scores is presented in the 
6
th
 Table below. 
Code Note 
100-91 Superior functioning in a wide range of activities, life’s problems never seem to get out of 
hand, is sought out by others because of his or her many positive qualities. No symptoms. 
 90-81 Absent or minimal symptoms, good functioning in all areas, interested and involved in a wide 
range of activities, socially effective, generally satisfied with life, no more than everyday 
problems or concerns. 
 80-71 If symptoms are present they are transient and expectable reactions to psychosocial 
stressors; no more than slight impairment in social, occupational, or school functioning. 
 70-61 Some mild symptoms OR some difficulty in social, occupational, or school functioning, but 
generally functioning pretty well, has some meaningful interpersonal relationships. 
 60-51 Moderate symptoms OR moderate difficulty in social, occupational, or school functioning in 
social, occupational, or school functioning. 
 50-41 Serious symptoms OR any serious impairment in social, occupational, or school functioning. 
 40-31 Some impairment in reality testing or communication OR major impairment in several areas, 
such as work or school, family relations, judgment, thinking, or mood. 
 30-21 Behavior is considerably influenced by delusions or hallucinations OR serious impairment in 
communication or judgment OR inability to function in almost all areas. 
 20-11 Some danger of hurting self or others OR occasionally fails to maintain minimal person 
hygiene OR gross impairment in communication. 
 10-01 Persistent danger of severely hurting self or others OR persistent inability to maintain 
minimal personal hygiene OR serious suicidal act with clear expectation of death. 
Table 6. GAF scoring interpretation 
GAF scores were estimated both at baseline and at discharge.  
 
Side-effects of pharmacotherapy 
• The Udvalg for Kliniske Undersogelser Rating Scale (UKU) (Lingjaerde, Ahlfors 
et al. 1987; Jordan, Knight et al. 2004) was used for the assessment of the side 
effects of medication, which is currently the most comprehensive instrument for 
assessing drug undesired effects. UKU is a clinician-assessed scale, evaluating 48 
symptoms in 4 categories; psychic, autonomic, neurologic and other. Side effects as 
rated with the UKU scale were only documented when considered by the clinician as 
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probable or possible related to pharmacotherapy and they were used to construct 
the UKU total scores. Additionally, the two subcategories of the UKU questionnaire, 
concerning the degree of impairment in the patient’s daily performance, separately 
evaluated both by the patient and the clinician, were also estimated. UKU measures 
at baseline and at discharge were used in the statistical analysis of the current study.  
4.5. STATISTICAL ANALYSIS 
An initial database with 1014 patients was used. After eliminating patients with 
bipolar disorder (62 subjects) a dataset with 952 patients was further filtered by only 
keeping patients with baseline Hamilton score at least equal to seven and side-
effects assessment. 773 subjects remained for data analysis: 
• Descriptive statistics, boxplots, and histograms were utilized for sample 
characteristics and data illustration.  
• Paired samples t-test was used to assess significance of change between pre- 
and posttreatment measurements. 
• Pearson correlation was used to assess significant relations between scores.  
• General linear regression models were used to determine the independent 
impact of demographic and pre- and posttreatment clinical variables on 
HRQol outcome. 
• Marginal means estimation was performed to assess pre-/posttreatment 
differences of outcome depending on severity of depression. 
• Chi-Square Tests were applied to explore significant relations of severity of 
somatic symptoms (mild, moderate, severe) to outcome measures. 
• Oneway ANOVA analysis was used to control residual somatic symptoms in 
relation to treatment response.  
P-values less than 0.05 were considered statistically significant. 
SPSS 17.0 (SPSS Inc., Chicago, IL) and Statistica 8.0 (Stat Soft Inc., Tulsa, OK) were 
used for data analysis.  
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5. RESULTS 
Sample characteristics 
The main socio-demographic and clinical variables of the sample are listed in the 
following table. 
Sample characteristics N % Mean SD 
Gender     
• Male 286  37,00   
• Female 487  63,00   
Age   44,81 12,07 
Age group     
• 18-30 115  14,88   
• 31-50 381  49,29   
• >51 277  35,83   
Response 535  69,21   
Remission 348  45,02   
Duration of hospitalisation 773  56,03 49,08 
Length of illness (years) 714    6,52   9,04 
Number of hospitalizations 762    1,44   2,05 
Age at onset 714  38,33 12,87 
Depression ICD-10     
• Mild   180  23,28   
• Moderate 349  45,15   
• Severe 244  31,57   
• Recurrent 432  55,89   
• Psychotic   66    8,54   
Comorbidities ICD-10 369 100   
• organic mental disorders     1    0,27   
• psychoactive substance use 
dependence disorders 
  92  24,93   
• schizophrenia , delusional 
disorders 
    1    0,27   
• affective disorders   56  15,18   
• neurotic, stress and 
somatoform disorders 
102  27,64   
• behavioural syndromes 
associated with physiological 
disturbance and physical 
factors 
   5    1,36   
• disorders of adult personality 
and behaviour 
112  30,35   
Table 7. Sample characteristics 
The gender distribution for the sample was 37% males and 63% females. Almost half 
of the patients (49.3%) belonged in the age group of 31-50 years. The mean age ± SD 
age was 44.8 ± 12, while the mean age at onset of the disease was estimated at 38.3 
± 12.8 years. The current hospitalization had a mean duration of 56 days. The mean 
illness duration was about 6.5 years, while the mean number of previous 
hospitalizations was 1.4. All patients had depression as a primary diagnosis. 
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According to ICD-10 criteria, 369 of them (47.7%) had psychiatric comorbidities, as 
listed above in Table 7.  
The distribution of the patients according to total HAMD-scores at baseline is shown 
in the histogram below (Figure 4).  
Figure 4. Distribution according to HAMD-17 scores  
The majority of subjects had a total HAMD baseline score above 18; in other words 
they suffered from moderate to severe major depression. 55.9% of the patients 
suffered from recurrent major depression, while 8.5% presented also psychotic 
features.  
According to posttreatment measures, 69.2% subjects were classified as responders; 
among them 24.2% were responders without remission and 45% remitters. 30.8% of 
the patients showed at study endpoint non-response to therapy.  
HAMD-17 pre 
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Study variables 
The main variables used in the study are shown in Table 8 below. The names of the 
variables are listed in detail in Table 2 in the annex.  
 
Descriptive statistics           N                 Mean       Std. Deviation 
HAMD pain item pre 773 1,42 ,70 
HAMD pain item post 773 ,75 ,70 
GAF pre 753 47,13 11,15 
GAF post 650 69,34 11,02 
Impair by patient pre 773 ,40 ,65 
Impair by patient post 773 ,87 ,70 
Impair by clinician pre 773 ,37 ,60 
Impair by clinician post 773 ,80 ,59 
UKU pre 773 2,18 3,49 
UKU post 773 2,94 3,30 
HAMD somatic pre 773 9,45 3,17 
HAMD somatic post 773 4,06 3,05 
HAMD-17 pre 773 21,79 5,63 
HAMD-17 post 773 9,09 6,71 
FLZ pre 446 -3,68 7,22 
FLZ post 351 3,61 7,92 
Physical Functioning SF-36 pre 152 60,66 24,19 
Physical Functioning SF-36 post 152 69,89 25,36 
Role-Physical SF-36 pre 152 16,28 29,93 
Role-Physical SF-36 post 152 29,77 37,48 
Bodily Pain SF-36 pre 152 17,43 10,76 
Bodily Pain SF-36 post 152 11,25 10,76 
General Health SF-36 pre 152 54,27 17,66 
General Health SF-36 post 152 64,22 15,11 
Vitality SF-36 pre 152 56,78 9,25 
Vitality SF-36 post 152 55,85 11,56 
Social Functioning SF-36 pre 152 47,24 13,05 
Social Functioning SF-36 post 152 50,51 12,27 
Role- Emotional SF-36 pre 152 7,21 19,90 
Role- Emotional SF-36 post 152 21,48 36,09 
Mental Health SF-36 pre 152 50,92 9,75 
Mental Health SF-36 post 152 57,16 10,38 
Physical component SF-36 pre 511 44,43 9,90 
Physical component SF-36 post 376 46,82 9,68 
Mental component SF-36 pre 511 22,42 8,41 
Mental component SF-36 post 376 32,58 11,73 
TOTAL SF36 pre 152 40,52 7,60 
TOTAL SF36 post 152 43,35 9,69 
Table 8. Descriptive statistics 
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All 773 patients of the sample had positive somatic scoring before treatment. 677 of 
them (87.5%) had also positive pain scoring.  
Histograms 
Figure 5. Distribution of patients according to somatic scoring pre- and posttreatment 
 
After treatment 65 patients had HAMD somatic symptom scoring equal to 0. 
The gender distribution in the remaining 708 patients with HAMD somatic >0 after 
treatment was as follows:  
HAMD somatic post >0 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid males 258 36,44 36,44 36,44 
 females 450 63,56 63,56 1000,0 
 Total 708 100,00 100,00 
 
Table 9. Gender distribution of patients with positive somatic scoring posttreatment 
Among patients with positive somatic scoring after treatment, pain was present in 
462 of them. The gender distribution for the 462 patients follows: 
HAMD pain item post >0 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid males 165 35,71 35,71 35,71 
 females 297 64,29 64,29 100,00 
 Total 462 100,00 100,00 
 
Table 10. Gender distribution of patients with pain posttreatment 
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Comparison of pre- and posttreatment scores 
Paired samples t-test used to compare scores and subscores before and after 
treatment revealed statistically significant differences (p<0.05) in scores for almost 
all values. Statistically significant values are highlighted in the 11th Table.  
 
  T df Sig. (2-tailed) 
Pair 1 HAMD pain item pre –           
HAMD pain item post 
22,18 773 ,00 
Pair 2 GAF pre – GAF post -39,35 640 ,00 
Pair 3 Physical component SF-36 pre- 
Physical component SF-36 post  
-4,58 327 ,00 
Pair 4 Mental component SF-36 pre-
Mental component SF-36 post 
-13,87 327 ,00 
Pair 5 Impair by patient pre-                  
Impair by patient post 
-17,28 773 , 00 
Pair 6 Impair by clinician pre-                  
Impair by clinician post 
-17,30 773 ,00 
Pair 7 Impair by patient pre-                  
Impair by clinician pre-                   
1,97 773 ,05 
Pair 8 Impair by patient post                
Impair by clinician post                   
5,24 773 ,00 
Pair 9 UKU pre- UKU post -5,45 773 ,00 
Pair 10 HAMD somatic pre-                
HAMD somatic post 
37,62 773 ,00 
Pair 11 HAMD 17 pre-  HAMD 17 post 44,22 773 ,00 
Pair 12 Physical Functioning pre- 
Physical Functioning post 
-4,53 152 ,00 
Pair 13 Role-Physical SF-36 pre-                 
Role-Physical SF-36 post 
-3,91 152 ,00 
Pair 14 Bodily Pain SF-36 pre-                   
Bodily Pain SF-36 post 
5,60 152 ,00 
Pair 15 General Health SF-36 pre- 
General Health SF-36 post 
-6.00 152 ,00 
Pair 16 Vitality SF-36 pre-                  
Vitality SF-36 post 
0,96 152 ,34 
Pair 17 Social Functioning SF-36 pre-       
Social Functioning SF-36 post 
-2,35 152 ,00 
Pair 18 Role- Emotional SF-36 pre-    
Role- Emotional SF-36 post 
-4,42 152 ,00 
Pair 19 Mental Health SF-36 pre-     
Mental Health SF-36 post 
-6,05 152 ,00 
Pair 20 TOTAL SF36 pre-                 
TOTAL SF36 post 
-3,44 152 ,00 
Pair 21 FLZ pre- FLZ post -13,69 271 ,00 
2 SF-36 major subscales 
8 SF-36 subscales 
1 SF-36 total score 
Table11 . Paired Samples Test 
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The main differences are illustrated graphically with boxplots (Figure 6). 
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Figure 6. Illustration of main pre- and posttreatment differences 
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Correlations of the variables 
The Pearson correlation coefficient was calculated for all scores before and after 
therapy. A positive correlation implies that large values for one score are more likely 
to correspond to large values for the other score while a negative correlation implies 
that large values for one score are more likely to correspond to small values for the 
other score. The clinically most important correlations are presented in the following 
tables and the statistically significant values are highlighted.  
A) Correlations before treatment 
 
Somatic symptoms at baseline were positive correlated to total HAMD-score, 
whereas they were negative associated to GAF score and of all SF-36 subscales only 
to the physical health major SF-36 subscale. Therefore, there was no direct 
association of somatic symptoms at baseline with total SF-36 and FLZ scores. In other 
words, somatic symptoms at baseline indicated a more severe depression, a worse 
physical health and a lower overall level of functioning, but not also a lower quality 
of life level.  
On the contrary, painful somatic symptoms at baseline (HAMD item 13) were 
negatively correlated to the total SF-36 and FLZ scores, as well as to all of the SF-36 
subscales, except from the subscales for vitality and mental health. Furthermore, 
there was a positive correlation of painful somatic symptoms with the total UKU and 
HAMD-17 scores. So, pain in specific indicated, besides a more severe depression, 
also a lower quality of life at baseline and a higher burden of medication.  
As far as total HAMD-17 was concerned, there was a negative correlation with the 
mental and physical health major subscales, as well as the FLZ scores, meaning that a 
more severe depression indicated a worse mental and physical condition and a lower 
quality of life. 
FLZ and SF-36 total scores, both indicating the quality of life level, had as expected a 
positive correlation with each other.  
UKU sumscore had no significant influence on SF-36 and FLZ measures, meaning that 
the medication side-effect burden did not correlate to the quality of life.  
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  HAMD 
pain item 
pre 
GAF pre 
 
 
Physical 
component 
SF-36 pre 
Mental 
component 
SF-36 pre 
HAMD 17 
pre 
 
UKU pre Pearson Correlation ,10** -,09* -,09 ,01  
 Sig. (2-tailed) ,00 ,01 ,053 ,827  
 N 773 753 511 511  
HAMD somatic pre Pearson Correlation ,32** -,17** -,16** -,05 ,73** 
 Sig. (2-tailed) ,00 ,00 ,00 ,29 ,00 
 N 773 753 511 511 773 
HAMD 17 pre Pearson Correlation ,27** -,27** -,14** -,13**  
 Sig. (2-tailed) ,00 ,00 ,00 ,00  
 N 773 753 511 511  
FLZ pre Pearson Correlation -,09* ,13** ,22** ,44** -,22** 
 Sig. (2-tailed) ,05 ,01 ,00 ,00 ,00 
 N 446 443 367 367 446 
Table 12a. Correlation of pretreatment variables 
 
  Physical Functioning 
SF-36 pre 
Role-Physical   
SF-36 pre 
Bodily Pain       
SF-36 pre 
HAMD pain item pre Pearson Correlation -,18* -,27** ,18* 
 Sig. (2-tailed) ,02 ,00 ,02 
 N 152 152 152 
Physical component SF-36 pre Pearson Correlation ,83** ,64** -,61** 
 Sig. (2-tailed) ,00 ,00 ,00 
 N 152 152 152 
Mental component SF-36 pre Pearson Correlation -,053 ,20* -,09 
 Sig. (2-tailed) ,52 ,01 ,28 
 N 152 152 152 
HAMD 17 pre Pearson Correlation -,08 -,18* ,10 
 Sig. (2-tailed) ,33 ,02 ,24 
 N 152 152 152 
FLZ pre Pearson Correlation ,15** ,11* -,13** 
 Sig. (2-tailed) ,00 ,02 ,01 
 N 446 446 446 
  General Health    
SF-36 pre 
Vitality SF-36 pre 
 
Social Functioning 
SF-36 pre 
HAMD pain item pre Pearson Correlation ,20* -,10 -,15 
 Sig. (2-tailed) ,01 ,23 ,07 
 N 152 152 152 
GAF pre Pearson Correlation -,03 -,02 ,14 
 Sig. (2-tailed) ,71 ,85 ,09 
 N 152 152 152 
Physical component SF-36 pre Pearson Correlation -,39** ,22** ,02 
 Sig. (2-tailed) ,00 ,01 ,86 
 N 152 152 152 
Mental component SF-36 pre Pearson Correlation -,20* ,09 -,14 
 Sig. (2-tailed) ,01 ,28 ,10 
 N 152 152 152 
FLZ pre Pearson Correlation -,21** ,03 -,09 
 Sig. (2-tailed) ,00 ,57 ,06 
 N 383 389 393 
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Table 12b. Correlation of pretreatment variables and SF-36 scores 
 
B) Correlations after treatment 
After treatment, residual somatic symptoms, painful and non-painful, were negative 
correlated with the social functioning, the mental and physical health main 
subscales, almost all of the rest SF-36 subscales, as well as the SF-36 and FLZ 
sumscores, indicating therefore a lower quality of life. Furthermore, they positive 
correlated to UKU and HAMD-17 sumscores. In other words, residual somatic 
symptoms indicated more severe depression and a higher medication side-effect 
burden posttreatment.  
Similarly to pretreatment findings, UKU scores had no significant impact on SF-36 
and FLZ measures, meaning that the medication side-effects did not significantly 
influence quality of life.  
  Impair by 
clinician post 
UKU post 
 
HAMD 
somatic post 
HAMD 17 post 
 
HAMD pain item 13 post Pearson Correlation ,03 ,21** ,59** ,59** 
 Sig. (2-tailed) ,44 ,00 ,00 ,00 
 N 773 773 773 773 
GAF post Pearson Correlation -,02 -,10** -,45** -,63** 
 Sig. (2-tailed) ,69 ,01 ,00 ,00 
 N 650 650 650 650 
Physical component SF-36 
post 
Pearson Correlation -,02 -,20** -,31** -,30** 
 Sig. (2-tailed) ,68 ,00 ,00 ,00 
 N 376 376 376 376 
  Role- Emotional 
SF-36 pre 
Mental Health   
SF-36 pre 
TOTAL SF-36 pre 
 
HAMD pain item pre Pearson Correlation -,18* -,08 -,24** 
 Sig. (2-tailed) ,03 ,31 ,00 
 N 152 152 152 
Physical component SF-36 pre Pearson Correlation ,33** ,23** ,62** 
 Sig. (2-tailed) ,00 ,00 ,00 
 N 152 152 152 
Mental component SF-36 pre Pearson Correlation ,45** ,38** ,20* 
 Sig. (2-tailed) ,00 ,000 ,01 
 N 152 152 152 
FLZ pre Pearson Correlation ,24** ,20** ,19** 
 Sig. (2-tailed) ,00 ,00 ,00 
 N 378 387 370 
HAMD somatic pre Pearson Correlation -,12 -,04 -,10 
 Sig. (2-tailed) ,14 ,60 ,22 
 N 152 152 152 
HAMD 17 pre Pearson Correlation -,15 -,08 -,13 
 Sig. (2-tailed) ,06 ,30 ,11 
 N 152 152 152 
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Mental component SF-36 post Pearson Correlation -,03 -,04 -,31** -,36** 
 Sig. (2-tailed) ,55 ,50 ,00 ,00 
 N 376 376 376 376 
Impair by patient post Pearson Correlation ,83** ,45** ,07 ,04 
 Sig. (2-tailed) ,00 ,00 ,05 ,29 
 N 773 773 773 773 
Impair by clinician post Pearson Correlation 1 ,43** ,00 -,03 
 Sig. (2-tailed)  ,00 ,94 ,44 
 N 773 773 773 773 
UKU post Pearson Correlation ,43** 1 ,18** ,18** 
 Sig. (2-tailed) ,00  ,00 ,00 
 N 773 773 773 773 
HAMD somatic post Pearson Correlation ,00 ,18** 1 ,87** 
 Sig. (2-tailed) ,94 ,00  ,00 
 N 773 773 773 773 
HAMD 17 post Pearson Correlation -,03 ,18** ,87** 1 
 Sig. (2-tailed) ,44 ,00 ,00  
 N 773 773 773 773 
Table 13a. Correlation of posttreatment variables 
 
  Physical 
Functioning SF-36 
post 
Role-Physical SF-36 
post 
 
Bodily Pain SF-36 
post 
 
HAMD pain post Pearson Correlation -,23** -,15 ,25** 
 Sig. (2-tailed) ,00 ,07 ,00 
 N 152 152 152 
GAF post Pearson Correlation ,23** ,03 -,29** 
 Sig. (2-tailed) ,01 ,69 ,00 
 N 151 151 151 
Physical component SF-36 post Pearson Correlation ,82** ,64** -,59** 
 Sig. (2-tailed) ,00 ,00 ,00 
 N 152 152 152 
Mental component SF-36 post Pearson Correlation ,09 ,28** -,20* 
 Sig. (2-tailed) ,30 ,00 ,02 
 N 152 152 152 
HAMD somatic post Pearson Correlation -,20* -,28** ,26** 
 Sig. (2-tailed) ,02 ,00 ,00 
 N 152 152 152 
HAMD-17 post Pearson Correlation -,33** -,29** ,24** 
 Sig. (2-tailed) ,00 ,00 ,00 
 N 152 152 152 
FLZ post Pearson Correlation ,13* ,09 -,20** 
 Sig. (2-tailed) ,02 ,08 ,00 
 N 351 351 351 
  General Health 
SF-36 post 
Vitality SF-36 post 
 
Social Functioning 
SF-36post 
HAMD pain item post Pearson Correlation ,33** ,02 -,20* 
 Sig. (2-tailed) ,00 ,81 ,01 
 N 152 152 152 
GAF post Pearson Correlation -,28** ,00 ,13 
 Sig. (2-tailed) ,00 ,98 ,12 
 N 151 151 151 
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Physical component SF-36 post Pearson Correlation -,38** ,07 ,06 
 Sig. (2-tailed) ,00 ,42 ,44 
 N 152 152 152 
Mental component SF-36 post Pearson Correlation -,26** -,12 ,01 
 Sig. (2-tailed) ,00 ,15 ,92 
 N 152 152 152 
UKU post Pearson Correlation ,19* ,04 -,13 
 Sig. (2-tailed) ,02 ,64 ,11 
 N 152 152 152 
HAMD somatic post Pearson Correlation ,39** -,03 -,12 
 Sig. (2-tailed) ,00 ,70 ,14 
 N 152 152 152 
HAMD 17 post  Pearson Correlation ,45** -,01 -,25** 
 Sig. (2-tailed) ,00 ,95 ,00 
 N 152 152 152 
FLZ post Pearson Correlation -,41** -,01 -,05 
 Sig. (2-tailed) ,00 ,92 ,42 
 N 308 309 310 
  Role- Emotional SF-36 post Mental Health SF-36 post 
HAMD pain item post Pearson Correlation -,16 -,20* 
 Sig. (2-tailed) ,05 ,01 
 N 152 152 
GAF post Pearson Correlation ,15 ,28** 
 Sig. (2-tailed) ,07 ,00 
 N 151 151 
Physical component SF-36 post Pearson Correlation ,12 ,12 
 Sig. (2-tailed) ,15 ,16 
 N 152 152 
Mental component SF-36 post Pearson Correlation ,71** ,47** 
 Sig. (2-tailed) ,00 ,00 
 N 152 152 
HAMD somatic post Pearson Correlation -,30** -,22** 
 Sig. (2-tailed) ,00 ,01 
 N 152 152 
HAMD 17 post Pearson Correlation -,31** -,31** 
 Sig. (2-tailed) ,00 ,00 
 N 152 152 
FLZ post Pearson Correlation ,25** ,15** 
 Sig. (2-tailed) ,00 ,01 
 N 292 307 
  TOTAL SF-36  post FLZ post 
HAMD pain item post Pearson Correlation -,17* -,25** 
 Sig. (2-tailed) ,04 ,00 
 N 152 351 
GAF post Pearson Correlation ,11 ,39** 
 Sig. (2-tailed) ,17 ,00 
 N 151 345 
Physical component SF-36 post Pearson Correlation ,50** ,33** 
 Sig. (2-tailed) ,00 ,00 
 N 152 286 
Mental component SF-36 post Pearson Correlation ,45** ,44** 
 Sig. (2-tailed) ,00 ,00 
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 N 152 286 
HAMD somatic post Pearson Correlation -,27** -,34** 
 Sig. (2-tailed) ,00 ,00 
 N 152 351 
HAMD 17 post Pearson Correlation -,34** -,45** 
 Sig. (2-tailed) ,00 ,00 
 N 152 351 
FLZ post Pearson Correlation ,26** 
 Sig. (2-tailed) ,00 
 N 284 
Table 13b. Correlation of posttreatment variables, FLZ and SF-36 scores  
Somatic symptoms and HRQol in relation to depression severity 
General linear model 
As already mentioned, all patients had HAMD>0 somatic scores before treatment 
and were split into three groups according to the severity of depression (mild 
depressed with HAMD-17 scoring between 7-17, moderate depressed with HAMD-
17 scoring between 18-24, and severe depressed with HAMD-17 scoring over 24). 
HAMD somatic scores differed significantly between the three groups of patients 
depending on depression severity, meaning that patients with more severe 
depression had a higher somatic symptom scoring before treatment.  
 
Within-Subjects Factors 
factor1 Dependent Variable 
1 HAMD somatic pre 
2 HAMD somatic post 
 
Between-Subjects Factors 
  
Value 
Label N 
HAMD categories mild 7-17 180 
 moderate 18-24 349 
 severe >25 244 
 
Tests of Within-Subjects Contrasts 
Measure:MEASURE_1 
Source factor1 F Sig. 
factor1 post vs. pre 1506,00 ,00 
factor1 * hamdcat post vs. pre 81,93 ,00 
 Table 14. HAMD somatic in mild, moderate and severe depressed patients 
 
HAMD somatic dropped significantly for all 3 categories (p<0.001). Categories scores 
dropped at a different rate (p<0.001). Categories with higher scores had higher 
slopes, indicating that more severe depressed patients had a higher degree of 
somatic symptom improvement posttreatment. 
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SF-36 was significantly higher after treatment (p<0.001), depicting a higher SF-36 
quality of life posttreatment. All 3 categories had similar slopes (p=0.46), indicating 
an equal rate of improvement in SF-36 quality of life with treatment, regardless of 
the severity of depression at baseline. 
 
Within-Subjects Factors 
Measure:MEASURE_1 
factor1 Dependent Variable 
1 TOTAL SF 36 pre 
2 TOTAL_SF-36 post 
 
Between-Subjects Factors 
  Value Label N 
HAMD categories mild 7-17 84 
 moderate 18-24 151 
 severe >25 93 
 
Tests of Within-Subjects Contrasts 
Source factor1 F Sig. 
factor1 post vs. pre 32,88 ,00 
factor1 * hamdcat post vs. pre ,78 ,46 
Table 15. SF-36 in mild, moderate and severe depressed patients 
 
All 3 groups had higher FLZ scores after treatment (p<0.001), which also indicates a 
higher FLZ quality of life after treatment. Groups with lower scores had higher 
slopes/acceleration (p=0.02). This means that less severe depressed patients showed 
a higher rate of improvement in FLZ quality of life with treatment. 
 
Within-Subjects Factors 
factor1 Dependent Variable 
1 FLZ pre 
2 FLZ post 
 
Between-Subjects Factors 
  Value Label N 
HAMD 
categories 
mild 7-17 66 
 moderate 18-24 128 
 severe >25 78 
 
Tests of Within-Subjects Contrasts 
Measure:MEASURE_1 
Source factor1 F Sig. 
factor1 post vs. pre 170,67 ,00 
factor1 * hamdcat post vs. pre 4,19 ,02 
 Table 16. FLZ in mild, moderate and severe depressed patients 
 
Estimated Marginal Means 
Before treatment HAMD somatic scores differed significantly between groups. After 
treatment categories 18-24 and >25 according to the HAMD-17 scoring did not differ 
significantly. However, the group of 7-17 had lower scores than the other 2, which 
means that the group of the less severe depressed patients had lower somatic 
symptom scoring than the other two posttreatment.  
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HAMD categories / HAMD somatic 
HAMD categories   95% Confidence Interval 
  Mean Std. Error Lower Bound Upper Bound 
7-17 pre 6,38 ,18 6,03 6,74 
 post 3,27 ,23 2,83 3,71 
18-24 pre 9,23 ,13 8,98 9,48 
 post 4,19 ,16 3,88 4,51 
>25 pre 12,03 ,15 11,72 12,33 
 post 4,44 ,19 4,06 4,82 
Table 17. Somatic symptom scoring pre- and posttreatment in mild, moderate and severe depressed 
patients 
Before treatment group >25 had marginally lower SF-36 score than group 7-17. After 
treatment each of the 3 groups raised their scores, which means an improvement in 
quality of life for all of the three groups after therapy. The SF-36 scores after 
treatment did not differ significantly between them (based on the 95% CIs that 
follow), meaning an equal level of SF-36 quality of life at endpoint regardless of the 
severity of depression at baseline. 
HAMD categories / TOTAL SF-36  
HAMD categories   95% Confidence Interval 
  Mean Std. Error Lower Bound Upper Bound 
7-17 pre 43,56 ,98 41,64 45,48 
 post 47,67 1,13 45,45 49,89 
18-24 pre 42,42 ,73 40,99 43,86 
 post 45,11 ,84 43,46 46,77 
>25 pre 39,86 ,93 38,04 41,68 
 post 44,25 1,07 42,14 46,36 
Table 18. TOTAL SF-36 pre- and posttreatment in mild, moderate and severe depressed patients 
FLZ before treatment is higher for group 7-17. After treatment FLZ scores do not 
differ significantly between groups, indicating an equal FLZ quality of life at endpoint 
regardless of the severity of depression at baseline. 
HAMD categories / FLZ 
HAMD categories   95% Confidence Interval 
  Mean Std. Error Lower Bound Upper Bound 
7-17 pre ,01 ,90 -1,77 1,77 
 post 4,70 ,99 2,74 6,65 
18-24 pre -3,60 ,64 -4,87 -2,34 
 post 3,38 ,71 1,97 4,78 
>25 pre -4,97 ,82 -6,59 -3,35 
 post 3,69 ,91 1,90 5,49 
Table 19. FLZ pre- and posttreatment in mild, moderate and severe depressed patients 
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Profile plots illustrate the differences as described above. 
 
 
 
Figure 7.Profile plots illustrating HAMD somatic, FLZ and SF-36 differences pre -and posttreatment in 
mild, moderate and severe depressed patients 
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Severity of somatic symptom scoring 
Chi-Square Tests 
All patients of our sample had at least few somatic manifestations before treatment. 
In order to explore differences at outcome in relation to the severity of the somatic 
symptoms pretreatment, the patients were classified in 2 categories, those with mild 
and those with severe somatic symptoms. Considering the median scores as the 
borderline for the two categories, the classification was as follows: scores ≤10 
referred to mild somatic symptom presentation and scores ≥11 to severe one. The 
two groups were controlled in relation to response, remission, SF-36, HAMD-17 and 
FLZ before and after treatment. Furthermore, the group of patients presenting with 
painful symptoms before therapy was tested separately for the same variables.  
Chi-Square Tests revealed significant relation of severity of somatic symptoms at 
baseline to severity of disease, but no significant relation to response, remission, 
TOTAL SF-36, FLZ scores.   
On the contrary, painful somatic symptoms showed a significant correlation to 
remission (p=0.032). More specific, pain before treatment implied lower true 
remission rates.  
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4,60a 1 ,03 
N of Valid Cases 773   
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Somatic symptom scoring posttreatment in relation to treatment response 
Oneway ANOVA analysis was used to control residual somatic symptoms in relation 
to treatment response. The patients were distributed in 3 groups: patients meeting 
the criteria for both remission and response (remitters), patients meeting the criteria 
for response but not remission (responders), and patients fulfilling the criteria 
neither for remission non response (non-responders).   
Mean scores were higher for responders than remitters and even higher for non-
responders, indicating worse treatment response in patients with more residual 
somatic symptoms. 
 
Residual somatic symptom scoring differs significantly between the three groups 
according to treatment response.  
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups 3905.249 2 1952.63 458.88 ,00 
Within Groups 3268.006 768 4.26   
Total 7173.256 770    
Table 21. Comparison of residual somatic in the 3 groups according to response 
 
Bonferroni adjustment was used for pairwise comparisons between the three 
groups. All three groups differ significantly (all p<0.05). 
Descriptives 
HAMD somatic post 
 
N Mean Std. Deviation Std. Error 
95% Confidence  
Interval for Mean 
     Lower Bound Upper Bound 
Non-responders 
 
236 7.19 2.86 .19 6.83 7.56 
Responders 
 
189 4.06 1.76 .13 3.81 4.32 
Remitters 
 
346 1.92 1.49 .08 1.76 2.08 
Total 771 4.06 3.05 .11 3.84 4.28 
 
Table 20. Residual somatic symptoms according to treatment response 
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Table 22. Pairwise comparisons of residual somatic symptoms in the 3 groups according to treatment 
response 
 
Figure 9. Illustration of residual somatic symptoms in the 3 groups according to therapy response 
Impact on HRQol outcome  
Univariate Analysis of Variance 
A hierarchical linear regression model was built with TOTAL SF-36 scores after 
treatment as the dependent variable and HAMD somatic pre, HAMD pain item pre, 
HAMD-17 pre, FLZ pre, sex, age, age at onset, years diseased, number of 
hospitalizations and psychiatric comorbidities as independent variables. 
Independent variables were assessed one by one as a first step. Variables with p<0.2 
were kept for the second step. All variables that were kept from the first step were 
entered in the model. Significant variables (p<0.05) were kept for the third step. FLZ 
pre, age, and years since condition's onset were significantly correlated with TOTAL 
SF-36 after treatment. The final model of the third step including only main effects 
follows: 
Ham_soma_99                                        Multiple comparisons 
Response to 
treatment 
 Mean Difference 
(I-J) Std. Error Sig. 
Non-responders Responders 3.13* .20 ,00 
 
Remitters 5.28* .17 ,00 
Responders Non-responders -3.13* .20             ,00 
 
Remitters 2.14* .19 ,00 
Remitters Non-responders -5.28* .17 ,00 
 
Responders -2.14* .19 ,00 
*. The mean difference is significant at the 0.05 level. 
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Table 23. The final regression model with the most important pretreatment dependent variables 
correlating with the TOTAL SF-36 at endpoint 
A similar hierarchical linear regression model was built with the TOTAL SF-36 scores 
after treatment as the dependent variable and HAMD somatic post, HAMD pain item 
post, HAMD-17 post, FLZ post, remission and response, sex, age, age at onset, years 
diseased, number of hospitalizations and psychiatric comorbidities as independent 
variables. Results for sex, age, age at onset, years with condition, number of 
hospitalizations, comorbidities still hold (as in the previous regression model). FLZ 
post, age, and sex were significantly correlated with TOTAL SF-36 after treatment.  
The final model including only main effects follows: 
Dependent Variable:TOTAL SF36 Score POST       Tests of Between-Subjects Effects 
Source Type III Sum of Squares df Mean Square F Sig. 
Corrected Model 4013,66a 3 1337,89 14,84 ,00 
Intercept 49496,99 1 49496,99 548,90 ,00 
sex 783,66 1 783,66 8,70 ,00 
FLZ post 2315,24 1 2315,24 25,68 ,00 
age 1428,07 1 1428,07 15,84 ,00 
Error 25249,07 280 90,18   
Total 612310,00 284    
Corrected Total 29262,73 283    
a. R Squared = ,137 (Adjusted R Squared = ,128) 
Table 24. The final regression model with the most important posttreatment dependent variables 
correlating with the TOTAL SF-36 at endpoint 
 
 
Dependent Variable:TOTAL SF36 Score POST         Tests of Between-Subjects Effects 
Source Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 2498,57a 3 832,86 8,76 ,00 
Intercept 40400,23 1 40400,23 424,84 ,00 
FLZ pre 700,21 1 700,21 7,36 ,01 
age 659,26 1 659,26 6,93 ,01 
Years diseased 538,45 1 538,45 5,66 ,02 
Error 22918,02 241 95,10 
  
Total 530310,00 245 
   
Corrected Total 25416,60 244 
   
a. R Squared = ,098 (Adjusted R Squared = ,087) 
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6. DISCUSSION 
6.1. SYNOPSIS OF RESULTS 
The current study is based on a dataset of 773 depressed inpatients, a subset of the 
primary 1079 enrolled in the multicenter trial. All patients were treated 
individualized and in accordance with the recommended psychiatric guidelines.  
Somatic symptoms, objective and subjective HRQol, global functioning, severity of 
depression, as well as pharmacotherapy side-effects were evaluated at baseline and 
at the end of the acute therapy phase. T-tests for the paired variables revealed 
significant pre- and posttreatment differences in almost all measures.  
Both somatic symptoms and severity of disease decreased significantly 
posttreatment. HRQol, life satisfaction as well as global functioning measures 
showed improvement. Somatic symptoms at baseline were associated with severity 
of depression. Specifically, painful somatic manifestations were shown as predictors 
for worse remission rates. Residual somatic symptoms, painful and non-painful ones, 
were associated with further HRQol impairments at the time of discharge. It was also 
found that residual somatic complaints were fewer in patients with better treatment 
response, as revealed their comparative study in remitters, responders and 
responders without remission. Although medication side effects increased 
posttreatment, they did not significantly correlate with life satisfaction and HRQol. 
The most significant influence on HRQol outcome at the end of the acute phase, 
according to the results of regression analyses, was attributed to age, patients´ life’s 
satisfaction, diseased years, and gender. 
The multiple correlations of the variables before and after treatment and their 
comparison with previous findings in the literature will thoroughly be discussed in 
the next section.  
 
 
 
  
 
56 6. DISCUSSION 
6.2. RESULTS IN VIEW OF PREVIOUS FINDINGS 
Somatic symptoms and pain  
The current study confirms, like previous ones, the outstanding high prevalence of 
somatic manifestations in clinical depression, since all of the 773 patients of our 
sample had positive somatic symptom scoring at baseline. In the literature, the 
presence of physical symptoms in depressed subjects has been estimated varying 
mainly between 69% and 92% (Ebert and Martus 1994; Simon, VonKorff et al. 1999; 
Corruble and Guelfi 2000; Allen, Gara et al. 2001; Kroenke 2003; Greco, Eckert et al. 
2004; Kroenke 2005; Tylee and Gandhi 2005). A naturalistic outpatient study in 
Puerto Rico reported also a 100% prevalence of somatisation in the depressed 
population (Tamayo, Roman et al. 2005).  
In our sample, 37% of the depressed subjects with somatic manifestations were 
males and 63% females. The gender distribution is similar to that of previous studies, 
which have shown that depression and somatising in depression are more common 
in females (Khan, Khan et al. 2003; Rhee, Holditch-Davis et al. 2005; Afridi, Siddiqui 
et al. 2009), with an almost constant male: female ratio at 1:2 (Weissman and 
Klerman 1977; Gater, Tansella et al. 1998).  
It is has to be noted that patients with severe physical comorbidities or organic cause 
of depression were excluded from the current study. The patients of our sample had 
depression as a primary diagnosis and received pharmacotherapy, according to 
earlier recommendations and individualized patient’s needs. It should be mentioned 
at this point that our patients were treated in tertiary care centres, like university 
and non-university hospitals, implying a more severe diseased population. Indeed, 
the majority of them suffered from moderate to severe depressive states, which is 
important, since the severity of depression has been associated with higher somatic 
scoring (Garcia-Campayo, Ayuso-Mateos et al. 2008). In addition, many of them had 
mental comorbidities of the Axis I, such as substance abuse (Mehrabian 2001), which 
have also been associated with increased somatisation rates (Ritsner 2003). These 
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facts could explain to some extent the 100% prevalence of somatic manifestations in 
our sample.  
Furthermore, 87.5% of our subjects had positive painful somatic symptom scoring at 
baseline. Especially pain complaints have been described in the literature as being 
very common in depression. They have been considered to represent at least half of 
the bodily symptoms in depressed subjects (Kroenke 2003), with a prevalence 
coming up to 60% (von Knorring 1975; Bair, Robinson et al. 2004) or 75%-80% 
(Vaccarino, Sills et al. 2009; Schneider, Linden et al. 2011), and in some cases 100% 
(Ward, Bloom et al. 1979). The variability of rates across the various studies probably 
reflects differences in patient selection, clinical setting and measuring methodology.  
Since somatic symptoms represent a part of the depression symptoms, they are 
expected to improve parallel with the other core depressive symptoms. We found 
that antidepressant therapy reduced significantly both mean somatic symptom 
scoring to the 42.9% of its initial value, as well as pain scoring approximately to the 
half of its initial value, although medication side effects had a simultaneous, but 
obviously weaker, adverse influence. Similarly, other studies, such as the ARTIST 
(Greco, Eckert et al. 2004) and the FINDER (Reed, Monz et al. 2009), revealed, 
parallel with the improvement of depression, a substantial drop in physical 
symptoms during the first weeks of therapy. 
It was mentioned that somatic symptoms at baseline correlated to severity of 
depression, which is consistent with earlier observations (Caballero, Aragones et al. 
2008). According to our results, the rate of improvement in somatic symptoms was 
relevant to depression severity at baseline, with increased disease severity showing 
greater physical symptom reduction. It should also be noted that lower depressed 
patients had finally lower somatic symptom scoring. These findings might imply that 
targeting a higher drop in the somatic symptom scoring could be helpful in the 
reduction of depression severity.  
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The severity of somatic symptoms at baseline, however, did not significantly 
correlate with response and remission rates in our study, at least at the time of 
discharge. It has already been observed that somatic symptoms at baseline do not 
predict the degree of reduction in HAMD scores during treatment and therefore 
treatment outcome (Denninger, Papakostas et al. 2006). This might be an implication 
for a more complex response of somatic symptoms to treatment. In the literature, 
the decrease in physical symptom scoring posttreatment has been considered not 
just as an epiphenomenon of depression improvement. The ARTIST study showed 
differential effects of physical symptoms and depression on HRQol, suggesting that 
physical symptoms should be considered at least as a somewhat separate entity 
from depressive symptoms(Greco, Eckert et al. 2004). Somatic symptoms have been 
thought to be also sensitive to a different mechanism of treatment when compared 
to the core affective depressive symptoms (Greco, Eckert et al. 2004).    
However, painful somatic symptoms have been shown to adversely affect 
treatment outcome and predict a poorer response in our subjects, which is also in 
accordance with previous reviews (Bair, Robinson et al. 2003; Kroenke 2003; Bair, 
Robinson et al. 2004). Recently, the PADRE study (Schneider, Linden et al. 2011) 
revealed that pain severity was strongly associated with a long-term reduction of 
depressive symptoms and that an early pain response had similar predictive value 
compared to early depression response for long term depressive outcome. The 
correlation specifically of pain among all somatic symptoms to poor therapy 
outcome could be in some way explained by the shared neurologic pathway of pain 
and depression (Basbaum and Fields 1978). Physical pain and depression have a 
deeper biological connection than simple cause and effect; the neurotransmitters 
that influence both pain and mood are serotonin and norepinephrine. Dysregulation 
of these transmitters is linked to both depression and pain, which may also explain 
the connection between painful somatic symptoms and depression. So, when a 
depressed subject complains of physical pain, there may be a chemical reason 
underlying. Under this consideration, antidepressants that inhibit the reuptake of 
both serotonin and norepinephrine, known as dual acting antidepressants, have 
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been used effectively in the treatment of chronic pain. However, their pain-relieving 
effects have been shown as independent of their mood-elevating properties (Chan, 
Fam et al. 2009). In a duloxetine trial, which is also a dual acting antidepressant, 
reduction of pain scores were considered equally attributable to the direct effect of 
duloxetine as well as to associated changes in depression severity (Nierenberg, 
Trivedi et al. 2004). It should be mentioned at this point that venlafaxine, which is a 
dual acting antidepressant like duloxetine, was the most often prescribed 
antidepressant in this naturalistic follow-up study.  
Moreover, some trials have shown that substances such as benzodiazepines and 
antipsychotics can also have antidepressant effects, suggesting that these effects 
could be attributable to non-specific pharmacological or psychological mechanisms 
of action (Khan, Leventhal et al. 2002). It is clear that the lack of placebo controls and 
the random assignment to antidepressants and other pharmacologic agents make it 
unlikely for the current study to resolve the issue of the true treatment effect of 
specific antidepressants on somatic symptoms any further.  
Therapy efficacy, response and remission rates, residual symptoms 
There are different ways to conceptualize the efficacy of an antidepressant 
treatment. In the current study pharmacological treatment was not specifically 
controlled; administration of medication was based on standard recommendations 
and individualized patients’ needs. Moreover, the lack of placebo control did not 
allow comparisons of true treatment effect vs. placebo. So, the effectiveness of the 
provided therapy was mainly evaluated by response and remission measures and 
their comparison with other findings described in the literature.  
Many trials with antidepressants have shown that full remission of the psychic and 
especially of the somatic symptoms in depressed patients can only be achieved for a 
minority of them within the acute phase treatment (Fava 2002; Moller, 
Demyttenaere et al. 2003; Thase 2003). A significant decrease in depression has 
been observed in many clinical trials after inpatient treatment (Greco, Eckert et al. 
2004; Gostautas, Pranckeviciene et al. 2006). We found that the mean HAMD-17 
total score in our sample decreased from 21.79 at baseline to 9.09 at final visit.    
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Lonnqvist and colleagues reported a reduction of the HAMD scale from 22 to 14 
after acute phase, corresponding to a major improvement (Lonnqvist, Sintonen et al. 
1994).  
About one third up to half of the patients has been described in the literature as 
responding to any given intervention, while only one third as achieving remission 
(APA 2000; Tranter, O'Donovan et al. 2002). According to our findings, 45% of the 
patients at study endpoint met the criteria for remission and 24.2% for response 
without remission, which are relative high rates. The most important explanation for 
this could be the long mean inpatient treatment duration (56 days), which is in 
accordance with previous recommendations for a minimum of 6 weeks therapy 
duration (Kupfer 1991), so that the optimal care benefit could be provided. Of 
course, we should take into account that our sample consisted mainly of moderate 
to severe depressed subjects. This is important, since patients with more severe 
depression at baseline, although more difficult to treat long-term, are expected to 
show during treatment the greatest overall levels of improvement (Moncrieff and 
Kirsch 2005). Conversely, patients with mild depression have been considered as less 
responsive to antidepressant therapy (NICE 2004). 
Gostautas and colleagues  (Gostautas, Pranckeviciene et al. 2006) reported about 
26% partial response and 57% remission rates in a sample of 87 patients after 
naturalistic inpatient treatment. A possible explanation for their somewhat higher 
rates could be that their sample, which was relative small, did not include subjects 
with psychotic features, which have been most often associated with resistance to 
therapy. Moreover, their results are not absolutely comparable to ours, since the 
evaluation of severity of symptoms and therefore the construction of the 
response/remission rates were based on different measuring instruments. 
In clinical practice, although a majority of patients respond to therapy with 
antidepressants, many of them suffer from residual symptoms (Tranter, O'Donovan 
et al. 2002), which are often somatic in nature (Fava 2003). These symptoms reflect 
a higher risk of relapse, and a more severe course of illness (Paykel, Ramana et al. 
1995; Judd, Akiskal et al. 1998; Mueller, Leon et al. 1999; Judd, Paulus et al. 2000; 
Kennedy and Paykel 2004), accompanied by increased impairments (Dunn and 
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Tierneey 2006), and a hampered objective and subjective quality of life 
(Kapfhammer 2006). Despite any outcome differences between studies, long 
duration of symptoms has been correlated with a negative treatment outcome 
(Keller, Klerman et al. 1984). Treating depression to remission is considered as a key 
component of adequate care (Dunn and Tierneey 2006). Especially, a rapid remission 
of depressive symptoms during the acute phase treatment was found as the 
strongest predictor for a favourable long term outcome (Gostautas, Pranckeviciene 
et al. 2006) and a significant strategy to prevent relapse and recurrence (Kennedy 
2007). 
In our study, although significant alleviation of depressive symptoms was observed, 
it remained at study endpoint a reservoir of somatic symptoms. Only 65 subjects had 
negative somatic symptoms scoring posttreatment, whereas the remaining 708 
patients had still at least few somatic manifestations.  Assessing residual somatic 
symptoms separately in remitters, responders without remission, and non-
responders revealed statistically significant differences between the groups. Indeed, 
residual somatic symptoms were fewer in responders without remission than non-
responders and even fewer in remitters. Similar findings showing fewer somatic 
symptoms in the group of remitters have already been reported (Denninger, 
Papakostas et al. 2006). Moreover, as reported by Greco and colleagues, remitters 
and responders showed significantly more change in painful and non-painful somatic 
symptoms than non-responders, 1 and 3 months from the beginning of 
antidepressant therapy (Greco, Eckert et al. 2004).  
So, as the improvement of somatic symptom parallels the overall improvement, 
somatic symptoms might indeed be a good overall proxymaker for treatment 
response, as has been recently shown in the PADRE study (Schneider, Linden et al. 
2011). As has already been suggested, the treatment of depressed patients with 
somatic symptoms should specifically target these symptoms in order to enhance 
remission rates (Fava 2003). It has also been reported that, in the acute treatment 
phase, the remission rate for patients who have at least 50% improvement in painful 
somatic symptoms is nearly twice that of depressed patients who have less than 50% 
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improvement in painful somatic symptoms, regardless of antidepressant treatment 
or placebo (Nierenberg, Trivedi et al. 2004). Therefore, better assessment and 
treatment of comorbid pain may enhance outcomes of depression therapy, which 
has also been supported in the literature (APA 2000; Ohayon 2004; Schneider, 
Linden et al. 2011).  
Health-related quality of life (HRQol) 
It has already been reported that disease-specific symptoms are responsible only for 
a restricted proportion of the variance in self-rated HRQol (Greco, Eckert et al. 2004; 
Rapaport, Clary et al. 2005), suggesting that improvement in depression and in 
HRQol are different concepts that do not necessary change hand in hand. However, 
major depression has been associated with substantial impairment in multiple 
domains of HRQol (Bech 1997; Barge-Schaapveld, Nicolson et al. 1999), which is in 
part directly attributable to the lowered mood (McCall, Cohen et al. 1999). Several 
studies have also shown that depression-related somatic symptoms have been 
positively correlated with impaired Qol (Luber, Meyers et al. 2001; Reed, Monz et al. 
2009). Nevertheless, our results showed that somatic symptoms before therapy in 
general were not, at least directly, associated with pretreatment quality of life 
measures. Neither side-effect scoring at baseline nor GAF measures showed a strong 
correlation with HRQol.  
In depression, one major problem is that subjective judgements are clearly 
influenced by actual mood state. So, in depressed subjects, besides general mood, 
thought and judgement are also heavily impaired. A depressed subject has a rather 
holistic negative perspective of life, without making clear distinctions or attributing 
the impairment on more specific domains. In that way, Qol measures are generally 
deteriorated and less prone to be strongly associated with other specific clinical 
variables. Since our sample consisted of moderately to severe depressed patients, 
and the evaluation of HRQol was based on self-rated measures, this influence of the 
depressed mood might have been more manifest before treatment.  
On the contrary, at study endpoint, residual somatic symptoms correlated with 
almost all domains of HRQol and life satisfaction. A possible explanation could be 
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that, as the mental health of the patients improved during therapy, they were more 
able to make judgements. In that way, they tended to attribute their impairment on 
more specific aspects, such as the presence of residual somatic symptoms.  
The impact of pain, however, on HRQol was more obvious both pre- and 
posttreatment. According to our analysis, painful somatic symptoms were shown to 
affect almost all domains of objective and subjective HRQol perception, as measured 
by means of SF-36 and FLZ, confirming previous findings. Pain has already been 
described to affect negatively HRQol perception (Munoz, McBride et al. 2005; Reed, 
Monz et al. 2009). Data analysis from the ARTIST study showed that increasing pain 
severity had an adverse impact on outcomes in multiple domains of HRQol (Bair, 
Robinson et al. 2004), as well as on patient satisfaction (Bair, Kroenke et al. 2007).  
In general, acute treatment of depression has been associated with significant 
improvement in multiple HRQol measures (Gostautas, Pranckeviciene et al. 2006; 
Reed, Monz et al. 2009). Studying Qol with the multidimensional instruments across 
domains has progressively gained ground, since different predictive models for the 
various Qol domains were found (Ay-Woan, Sarah et al. 2006). When the change in 
each of the two major SF-36 subscales (the mental and physical one) in our sample 
was compared, it was observed that both improved, but the mental component 
showed a greater improvement than the physical one. Furthermore, as far as the 8 
SF-36 subscales are concerned, emotional role-functioning subscale showed the 
greater improvement. Vitality was the only one domain which slightly deteriorated, 
but the change was statistically insignificant. This could be possibly attributed to the 
sedative effects of the administered pharmacological agents. The mean SF-36 
sumscore, on the other hand, had at endpoint a moderate but statistically significant 
increase. This does not question or mitigate, however, the effect of the treatment, 
since HRQol is prone to change for a longer period of time after the acute phase 
treatment.  Whereas physical symptoms have been expected to show the maximal 
change within the acute phase treatment (Greco, Eckert et al. 2004), HRQol have 
shown a longer change, even months after the beginning of therapy. So, perhaps 
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longer time is needed before the maximum treatment outcome becomes manifest 
(Goldberg 1997). 
To explore the most important clinical and sociodemographic variables on SF-36 
HRQol outcome, we conducted a regression analysis, with total SF-36 scores after 
treatment as the dependent variable and independent variables the following: FLZ 
life satisfaction pre- and posttreatment, somatic symptoms pre- and post-treatment, 
pain pre- and posttreatment, severity of depression (HAMD-17) pre- and 
posttreatment, remission, response, age, gender, diseased years, number of 
hospitalizations and psychiatric comorbidities. In the final model of the analysis, FLZ 
pre-and posttreatment, age, sex and diseased years were significantly correlated 
with the SF-36 quality of life posttreatment. More specific, FLZ pre- and 
posttreatment had a positive correlation to SF-36 after therapy, while older age and 
more diseased years of the patient had a negative one. Additionally, the male gender 
showed a higher SF-36 quality of life after therapy.  
It has already been reported that, although physical symptoms and depression 
impacted interactive on some of HRQol domains, adding them to a regression 
model, after adjustments for age, gender, race, anxiety, and comorbidities, produced 
only a slight change in variance (Greco, Eckert et al. 2004). The results of a similar 
regression analysis showed age, among demographic factors, as having the strongest 
impact on HRQol, while psychiatric comorbidities did not seem to influence 
outcome, similarly to our findings.  
Another important parameter of the quality of life is the global functioning 
assessment (GAF). It has already been mentioned that treatment should target not 
only at elimination of disease symptoms but also at restoration of the previous 
functioning level. GAF measures showed also significant improvement with therapy. 
The mean score increased from 47 at baseline (indicating serious symptoms or any 
serious impairment in social, occupational, or school functioning) to 69 at discharge. 
Posttreatment score indicated marginally only some mild symptoms or some 
difficulty in social, occupational, or school functioning, but generally pretty well 
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functioning, and meaningful interpersonal relationships. So, at the end of the acute 
phase, patients did regain their functional capacity for the most parts. 
Somatic symptoms, pain, and the burden of pharmacotherapy 
Side effects have been consistently considered as a key factor (Demyttenaere 2003), 
contributing to patient non-compliance (Fitzgerald 1976; Johnson 1981; 
Fleischhacker, Meise et al. 1994) and pharmacotherapy discontinuation in 30% to 
60% of the cases (Anderson and Tomenson 1995; Menting, Honig et al. 1996). 
Despite the evident beneficial effect of pharmacotherapy, the problem of the 
undesired reactions has been important for the development of safer medicines. So, 
there is growing evidence that post marketing evaluation of FDA-approved 
medications should be inclusive in clinical evaluations. 
It should be noted at this point that the side effect assessment comes up against the 
difficulty of distinguishing between somatic symptoms and pain caused by 
depression and those caused by treatment (Gruwez, Gury et al. 2004). Somatic 
(painful and non-painful) antidepressant adverse reactions may resemble the 
symptoms of major depression. Vice versa, somatic symptoms and pain in major 
depression may be interpreted by the patients as side-effects of their medication 
(Balon 1999).  
In the current study, the side-effect burden of pharmacotherapy was also taken into 
consideration; UKU measures, which have been considered as the standard 
evaluation ratings of antipsychotic side-effects, were conducted both at admission 
and discharge and the results were correlated with the other clinical ratings. As 
described in previous section, the UKU measures included evaluations of symptom 
severity, when a specific symptom was perceived as side-effect. Moreover, the 
global impairment of patients’ daily activities because of the undesired drug effects 
was assessed separately by the patient and by the clinician.  
We have to mention that before treatment there were already positive UKU 
ratings, although the inpatient pharmacotherapy had not yet been started. This 
could be attributed to two main reasons. From the one hand, the majority of the 
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naturalistically treated patients had already received medication before admission 
and might be experiencing the adverse effects of the outpatient pharmacotherapy. 
On the other hand, it is clear that many of the adverse effects that are attributed to 
psychopharmaca overlap to some extend with the psychic, cognitive and affective 
features of depression.  Symptoms that resemble side-effects have been described 
in the literature as being very common in depression even prior to any treatment 
(Barge-Schaapveld, Nicolson et al. 1999).  
The existence of painful somatic symptoms in particular was positively correlated to 
higher side-effect scoring pretreatment. This may imply that clinicians tend to 
underrecognize to some extend the high prevalence of non-organic pain in 
depression and attribute the reported painful symptoms rather to previous 
pharmacotherapy than to the depressive disorder itself. It has also been reported 
that physicians tend to associate pain with depression to a significantly lesser 
extent than any other somatic symptom (Caballero, Aragones et al. 2008). 
There was no apparent interplay between somatic symptoms at baseline and side 
effect scoring. But, although somatic symptoms significantly decreased at the time of 
discharge, residual somatic symptoms, either painful or non-painful ones, were 
significantly correlated with increased depression severity posttreatment and 
increased side-effect burden. These might imply, on the one hand, that clinicians 
tend to perceive some residual somatic symptoms as possible pharmacotherapy 
side-effects. On the other hand, it could be possible that patients with residual pain 
and depression are more difficult to treat and require higher antidepressant dosages 
or more medication and therefore also experience more side effects. It could also be 
alleged that mentally improved patients are able to distinguish more clearly 
symptoms deriving from their disease rather than medication. 
Another important observation concerns the perceived impairment of the all-day 
activities, as evaluated by the patient and by the clinician at baseline and at 
discharge. Before treatment, there was a marginally significant difference between 
clinician and patient ratings, with patients perceiving a greater side-effect burden. 
This is in agreement with the literature, since patients have been consistently 
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described to perceive generally more symptoms as side-effects and rate symptoms 
as more severe than the clinician (Lindstrom, Lewander et al. 2001). A recent 
outpatient study conducted in Rhodes (Zimmerman, Galione et al. 2010) showed 
that the mean number of side effects reported by the patients was 20 times higher 
than the number recorded by the psychiatrists; when the self-reported side effects 
were limited to frequently occurring or very bothersome side effects, the rate was 
still 2 to 3 times higher. In our study, the prementioned difference between patient 
and clinician side-effect burden perception increased further to strongly significant 
after therapy. This might depicts a further stronger tendency specifically of 
inpatients to attribute more adverse effects burden to their treatment. Besides, as 
mentioned above, the mentally improved patients at discharge may be able more 
clearly to perceive residual somatic manifestations as a part of the pharmacotherapy 
induced impairments.  
It is also interesting to mention that, unlike previous findings, our study did not 
reveal any important impact of perceived side effects on quality of life measures, 
either at baseline or at discharge. Wolters et al. (Wolters, Knegtering et al. 2009) on 
the contrary, who used multiple side-effect scales to assess antipsychotic side-effect 
burden, reported significant correlations of side-effect measures to quality of life. It 
has to be mentioned that maximal changes in HRQol were expected further after our 
study endpoint. As HRQol improves, further possible influences on outcome might 
become more manifest. The prementioned difference comparatively to our findings 
could also be attributed to the different scales that were used by Wolters, which 
were self-rated, had different scope, number of items and subscales, as well as 
internal reliability, concurrent and conceptual validity.  
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6.3. STRENGTHS AND LIMITATIONS  
• STRENGTHS 
The large sample size is a major strength of the current study.   
The good generalizability of the naturalistic study design is a further strength. The 
effectiveness of antidepressive therapy has already been shown by randomized 
controlled trials (RTCs). However, since such studies may underestimate the 
complexities of practice in the real world patients, the treatment efficacy might not 
reflect or guarantee the proper or effective use of antidepressants in clinical 
practice. The strict exclusion criteria of RTCs and their highly selected study subjects, 
which are not representative for the patients treated under routine clinical care, are 
responsible for their limited outcome generalizability. In contrast, the naturalistic 
model of our study provides information of the ``real world’’ clinical practice and 
depicts treatment effectiveness in more generalizable terms.  
Moreover, the self-rated HRQol measures, which were used in the current analysis, 
have the advantage, against the interviewer-rated ones, of not being susceptible to 
bias introduced by different interviewers (Stewart, Hays et al. 1988; Spitzer, Kroenke 
et al. 1999). This might be of great importance particularly in the case of multicenter 
trials, where many clinicians in differing clinical settings are involved, as in the 
current one. 
We should also mention the prospective collection of our data, which provides us 
with up-to-date information and the opportunity to control and enrich the current 
results to a constantly broadened sample. 
 Finally, we should point out the independent funding of the trial by the German 
Federal Ministry for Education and Research BMBF (01GI0219), which had no further 
role in study design, in the collection, analysis and interpretation of data, in the 
writing of the current thesis and in submitting the correspondent publication. 
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• LIMITATIONS 
The major limitation of this study is that it is a post hoc analysis of a prospective 
study, thus precluding definitive conclusions. It has been known that whenever a 
study deviates from the original hypothesis to evaluate a subset of the study 
population, the investigators increase the risk of finding a difference where none 
exists. So, special care is demanded in the interpretation of the results. 
At this point, we have to mention also the reduced internal validity of our study, 
because of the lack of a control group. The naturalistic design leads, despite its 
benefits, to scientifically less rigorous results than those of RTCs (Gostautas, 
Pranckeviciene et al. 2006). In the absence of placebo treatment, for example, it is 
not possible to assess the impact of somatic symptoms on true drug therapy 
response versus placebo response, or conversely the impact of true drug therapy on 
somatic symptoms.  
Moreover, the depressive states that we assessed were epidemiologically not 
representative of the general depressed population. The sample of the study 
consisted of inpatients, a group with more severe depressive states, and among 
them subjects that were hospitalized at university settings, therefore of the most 
severe or difficult to treat cases. Of course, we should mention the inability to 
generalize our results to old or very old population.  
Furthermore, the current analysis involves results until the end of the acute phase 
treatment with a mean duration of 7-8 weeks. But the use of HRQol measures raises 
problems as regards evaluations in short-term clinical trials, since serious 
improvement in quality of life requires some time. External conditions such as work, 
education, finances and housing are usually not subject to quick change. So, the 
optimal benefits of treatment may require up to several months to become manifest 
(Goldberg 1997). 
We also consider as a limitation the fact that the administered medication was not 
assessed in detail, for example the agent and its dose on an individual level, which 
hinders an exact interpretation of the side effects. 
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Finally, it has also been stated that clinical trials assessing quality of life should 
include both general and disease-specific instruments (Patrick and Deyo 1989; 
Wisniewski, Rush et al. 2007). Our HRQol measures involved only generic 
instruments. In addition, they were self-rated, and may therefore be influenced by 
the patients’ overall depression severity, hindering a differentiated evaluation of 
their true symptoms.  
6.4. CONCLUSIONS 
Summarizing, we could conclude the following: 
• Besides the core depressive symptoms, depression-related somatic 
manifestations play a significant and rather complex role in treatment outcome. 
Somatic symptoms at baseline are associated with increased depression severity. 
Among them, painful ones are strong predictors for lower remission rates. Residual 
somatic symptoms, painful and non-painful ones, are also associated with less 
favourable treatment response and further HRQol impairments at the time of 
discharge. 
• Inpatient treatment has a favourable effect on depression severity, HRQol, 
somatic manifestations and global functioning. When studying the effect in domains, 
the improvement in mental components appears stronger than in physical ones. In 
general, the acute inpatient treatment for depression could be considered beneficial 
for the patients and the pharmacotherapy good tolerated.  
• When somatic symptoms are present in depression, they need first of all to 
be correctly recognized. Secondly, they have to be treated correctly, parallel with the 
other depressive symptoms (e.g. with dual acting antidepressants plus 
psychotherapy) to achieve an optimal clinical outcome. Thirdly, patients need to be 
thoroughly informed about the origin and nature of their somatic symptoms (either 
possible side effects or residual symptoms) in order to prevent "doctor shopping" in 
the future. Such a holistic approach may improve the inpatient care in the future, 
reduce health costs and enhance both patient´s and clinician´s satisfaction. 
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6.5. SUGGESTIONS FOR FUTURE RESEARCH  
Somatic symptoms have been proven as important factors in depression. As there is 
still confusion about their exact role in treatment outcome, more research is 
required in this field.   
Since optimal benefits of treatment may require up to several months to become 
manifest (Goldberg 1997), as already mentioned, somatic symptoms as well as 
health-related quality of life may change a long time after therapy. So, we should 
emphasize on the need for longitudinal and long-term therapy assessments. 
Moreover, a more extensive study of somatic symptoms in groups, by using specific 
somatic symptom scoring instruments, might also be helpful to reveal possible 
effects of each specific symptom group on therapy response. As far as the concept of 
quality of life is concerned, it is very complex and multidimensional and could be 
more efficiently assessed by both general and disease specific instruments. 
Conclusively, similar attempts, studying long-term results, using more specific 
somatic symptom instruments and assessing both general and depression-specific 
HRQol measures could perhaps enhance a better understanding of the factors that 
might influence the treatment outcome in a major depressive episode and, 
therefore, be potentially helpful in patient management in the future.  
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8. ANNEX 
8.1 TABLES 
ICD-10 criteria of Major Depression 
 
Typical  
symptoms 
- depressed mood 
- loss of interest and enjoyment 
- psychomotor retardation, fatigability 
 
 
Other usual 
symptoms 
- reduced concentration and attention 
- reduced self-esteem and self-confidence 
- ideas of guilt and worthlessness bleak and pessimistic future  perspectives  
-  ideas or attempts of self-harm or suicide 
- sleep disorders 
- decreased appetite, loss of weight 
Severity of major depression 
Mild at least 2 typical und 2 usual symptoms 
Moderate  at least 2 typical und 3 usual symptoms 
Severe at least 3 typical und 4 usual symptoms 
       Table 1a. ICD-10 diagnostic criteria and severity of major depression 
 
      Table 1b. DSM-IV diagnostic criteria of major depression 
 
 
 
 
 
 
DSM-IV criteria of Major Depression 
At least 5 of the following symptoms, 1) for at least a 2-week period, and 2) at least one of 
the symptoms is either depressed mood or loss of pleasure 
1. Depressed mood  
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every day 
4. Insomnia or hypersomnia  
5. Psychomotor agitation or retardation   
6. Fatigue or loss of energy  
7. Feelings of worthlessness or excessive or inappropriate guilt  
8. Diminished ability to think or concentrate, or indecisiveness  
9. Recurrent thoughts of death, recurrent suicidal ideation, or a suicide attempt  
The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning 
The symptoms are not due to the direct physiological effects of a substance or a general 
medical condition  
The symptoms are not better accounted for by bereavement 
  
 
84 8. ANNEX 
 
 
HAMD pain item pre Hamilton item 13 for painful somatic symptoms pretreatment 
HAMD pain item post Hamilton item 13 for painful somatic symptoms posttreatment 
GAF pre Global Assessment of Functioning score pretreatment 
GAF post Global Assessment of Functioning score posttreatment 
Impair by patient pre Patient-rated impairment of daily performance pretreatment 
Impair by patient post Patient-rated impairment of daily performance posttreatment  
Impair by clinician pre Clinician-rated daily performance impairment pretreatment 
Impair by clinician post  Clinician-rated daily performance impairment posttreatment 
UKU pre UKU sumscore (side-effect burden) pretreatment 
UKU post UKU sumscore (side-effect burden) posttreatment 
HAMD somatic pre Hamilton somatic scoring pretreatment 
HAMD somatic post Hamilton somatic scoring posttreatment 
HAMD-17 pre Hamilton 17-item sumscore pretreatment 
HAMD-17 post Hamilton 17-item sumscore posttreatment 
FLZ pre FLZ sumscore pretreatment 
FLZ post FLZ sumscore posttreatment 
Physical Functioning SF-36 pre  
 
 
The 8 subscales of SF-36,  
each of them pre- and posttreatment  
Physical Functioning SF-36 post 
Role-Physical SF-36 pre 
Role-Physical SF-36 post 
Bodily Pain SF-36 pre 
Bodily Pain SF-36 post 
General Health SF-36 pre 
General Health SF-36 post 
Vitality SF-36 pre 
Vitality SF-36 post 
Social Functioning SF-36 pre 
Social Functioning SF-36 post 
Role- Emotional SF-36 pre 
Role- Emotional SF-36  post 
Mental Health SF-36 pre 
Mental Health SF-36 post 
Physical component SF-36 pre The 2 major SF-36 subscales: physical component and 
mental component 
each of them pre- and posttreatment 
Physical component SF-36 post 
Mental component SF-36 pre 
Mental component SF-36 post 
TOTAL SF36 pre Sumscore SF-36 pre- and posttreatment 
 TOTAL SF36 post 
Table 2. Descriptive variables 
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Medication class % 
of the 
sample 
(N%) 
Antidepressant 
agent 
% 
of the 
sample 
(N%) 
Non- 
pharmacologic 
treatments 
% 
of the 
sample 
(N%) 
Antidepressants 95.6 Venlafaxine 36.2 CBT 24.4 
Neuroleptics 42.5 Mirtazapine 23.0 Physiotherapy 21.7 
Tranquillizers  57.1 Sertraline 16.8 Occupational  
therapy 
17.2 
Hypnotics 42.3 Citalopram 15.0 Art and music  
therapy 
11.1 
Lithium 20.1 Trimipramine 11.9 ECT   2.6 
Other psycho-
pharmacologic 
compounds 
  0.3 Amitryptiline 11.6 Sleep deprivation   5.1 
  Reboxetine 7.8 Light-therapy   0.9 
  Doxepine 6.5 TMS   0.8 
  Paroxetine 5.1   
  Tranylcypromine         4.0   
Table 3. Administered medication in % of the studied sample 
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8.2 ABBREVIATIONS 
  
APA American Psychiatric Association 
ASRI allosteric serotonin reuptake inhibitor 
BDI Beck Depression Inventory 
DBS Deep brain stimulation 
DSM Diagnostic and Statistical Manual of Mental Disorders 
ECT Electroconvulsive Therapy 
FLZ Fragebogen zur Lebenzufriedenheit 
GAF Global Functioning Scale 
HAMD Hamilton Depression Scale 
HRQol Health-related Quality of Life 
ICD International Classification of diseases 
IDS Inventory of Depressive Symptomatology 
LQLP Lancashire Quality of life Profile 
LQF Quality of life questionnaire 
MADRS Montgomery-Asberg Depression Rating Scale 
MAOI Monoamine Oxidase Inhibitor 
TMS Transcranial magnetic stimulation 
MD Major depression 
MDD Major depressive disorder 
MOS Medical Outcomes Study 
NaSSA noradrenergic and specific serotonergic antidepressant 
NHP Nottingham Health Profile 
NICE National Institute of Health and Clinical Experience 
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NIMH National Institute of Mental Health 
NRI norepinephrine reuptake inhibitor 
NDM norepinephrine and dopamine modulator 
Qol Quality of life 
RIMA reversible inhibitor of MAO-A 
SF-36 Short form 36 
SNRI serotonin and norepinephrine reuptake inhibitor 
SSRI selective serotonin reuptake inhibitor 
TCA tricyclic antidepressant 
UKU Udvalg for Kliniske Undersogelser rating scale 
WHO World Health Organisation 
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8.3. QUESTIONNAIRES 
 
HAMILTON DEPRESSION SCALE (HAMD) 
 
SF 36 - FRAGEBOGEN ZUM GESUNDHEITSZUSTAND 
 
FLZ - FRAGEBOGEN ZUR LEBENSZUFRIEDENHEIT 
 
UDVALG FOR KLINISKE UNDERSOGELSER RATING SCALE (UKU) 
Kompetenznetzwerk „Depression, Suizidalität“ 
 
 
Patient / Code: H-____-S61-0   Datum: ____-___-20___   Termin A/W/E /K: ____   Rater: ____ 
 
„Depression,  Suizidalität“ 
 Hamilton Depression Scale (HAMD) 
 
1. Depressive Stimmung (Gefühl der Traurigkeit, Hoffnungslosigkeit, 
Hilflosigkeit, Wertlosigkeit) 
 
0: Keine  
1: Nur auf Befragen geäußert 
2: Vom Patienten spontan geäußert 
3: Aus dem Verhalten zu erkennen (z.B. Gesichtsausdruck, 
Körperhaltung, Stimme, Neigung zum Weinen)  
4: Patient drückt fast ausschließlich diese Gefühlszustände in seiner 
verbalen und nonverbalen Kommunikation aus 
 
2. Schuldgefühle 
 
0:  Keine 
1: Selbstvorwürfe, glauben Mitmenschen enttäuscht zu haben 
2:  Schuldgefühle oder Grübeln über frühere Fehler und „Sünden“.  
3:  Jetzige Krankheit wird als Strafe gewertet, Versündigungswahn 
4:  Anklagende oder bedrohende akustische / optische Halluzinationen 
 
3. Suizid (jeder ernste Versuch = 4) 
 
0:  Keiner 
1:  Lebensüberdruß 
2:  Todeswunsch, denkt an den eigenen Tod  
3:  Suizidgedanken oder entsprechendes Verhalten. 
4:  Suizidversuche 
 
4. Einschlafstörungen 
 
0:  Keine 
1:  Gelegentliche Einschlafstörungen (mehr als ½ Stunde) 
2:  Regelmäßige Einschlafstörungen 
 
5. Durchschlafstörungen 
 
0:  Keine 
1:  Patient klagt über unruhigen oder gestörten Schlaf 
2:  Nächtliches Aufwachen bzw. Aufstehen (falls nicht nur zur Harn- oder 
Stuhlentleerung) 
 
6. Schlafstörungen am Morgen 
 
0:  Keine 
1:  Vorzeitiges Erwachen, aber nochmaliges Einschlafen 
2:  Vorzeitiges Erwachen ohne nochmaliges Einschlafen 
 
7. Arbeit und sonstige Tätigkeiten (Arbeit oder Hobbies) 
 
0:  Keine Beeinträchtigung 
1:  Hält sich für leistungsunfähig, erschöpft oder schlapp bei seinen 
Tätigkeiten oder fühlt sich entsprechend 
2:  Verlust des Interesses an seinen Tätigkeiten, muß sich dazu zwingen. 
Sagt das selbst oder läßt es durch Lustlosigkeit, 
Entscheidungslosigkeit  oder sprunghafte Entschlusslosigkeit 
erkennen.     
3:  Wendet weniger Zeit für seine Tätigkeiten auf oder leistet weniger. Bei 
stationärer Behandlung „3“ ankreuzen, wenn der Patient weniger als 3 
Stunden an Tätigkeiten teilnimmt. Ausgenommen Hausarbeiten auf 
der Station 
4:  Hat wegen der Krankheit mit der Arbeit aufgehört. Bei stationärer 
Behandlung ist „4“ anzukreuzen, falls der Patient an keinen 
Tätigkeiten teilnimmt, mit Ausnahme der Hausarbeit auf der Station, 
oder wenn der Patient die Hausarbeit nur unter Mithilfe leisten kann 
 
8. Depressive Hemmung (Verlangsamung von Denken und Sprache, 
Konzentrationsschwäche, reduzierte Motorik) 
 
0: Sprache und Denken normal  
1: Geringfügige Verlangsamung bei der Exploration 
2: Deutliche Verlangsamung bei der Exploration  
3: Exploration schwierig. 
4: Ausgeprägter Stupor 
 
9. Erregung 
 
0: Keine 
1: Zappeligkeit  
2: Spielen mit den Fingern, Haaren, usw.  
3: Hin- und Herlaufen, nicht still sitzen können 
4: Händeringen, Nägelbeißen, Haareraufen, Lippenbeißen, usw. 
 
10. Angst - psychisch 
 
0:  Keine Schwierigkeiten 
1:  Subjektive Spannung und Reizbarkeit 
2:  Sorgt sich um Nichtigkeiten 
3:  Besorgte Grundhaltung, die sich im Gesichtsausdruck und in der 
Sprechweise äußert 
4:  Ängste werden spontan vorgebracht 
 
11. Angst – somatisch (körperliche Begleiterscheinungen der  Angst, 
z.B. kardiovaskuläre, Herzklopfen, gastrointestinale, Mundtrockenheit, 
Verdauungsstörungen, Durchfall, Krämpfe, respiratorische, 
Hyperventilation, Schwitzen, usw.) 
 
0: Keine 
1: Geringe 
2: Mäßige 
3: Starke 
4:  Extreme (Patient ist handlungsunfähig) 
12. Körperliche  - gastrointestinale 
 
0: Keine 
1: Appetitmangel, ißt aber ohne Zuspruch 
2: Muß zum Essen angehalten werden. Verlangt oder benötigt 
Abführmittel oder andere Magen-Darm-Präparate 
 
13. Körperliche Symptome – allgemeine 
 
0: Keine 
1: Schweregefühl in den Gliedern, Rücken oder Kopf. Rücken-, 
Kopf- oder Muskelschmerzen. Verlust der Tatkraft, 
Erschöpfbarkeit 
2: Bei jeder deutlichen Ausprägung eines Symptoms  
„2“ ankreuzen! 
 
14. Genitalstörungen (z.B. Libidoverlust, Menstruations- 
störungen) 
 
0: Keine 
1: Geringe 
2: Starke 
 
15. Hypochondrie 
 
0: Keine 
1: Verstärkte Selbstbeobachtung (auf den Körper bezogen) 
2: Ganz in Anspruch genommen durch Sorgen um die eigene 
Gesundheit 
3: Zahlreiche Klagen, verlangt Hilfe usw. 
4: Hypochondrische Wahnvorstellungen 
 
16. Gewichtsverlust (entweder A oder B ankreuzen) 
 
A. aus Anamnese 
 
0: Kein Gewichtsverlust 
1: Gewichtsverlust wahrscheinlich in Zusammenhang mit jetziger 
Krankheit 
2 Sicherer Gewichtsverlust laut Patient 
 
B. Nach wöchentlichem Wiegen in der Klinik, wenn 
Gewichtsverlust 
 
0: weniger als 0,5 kg / Woche 
1: mehr als 0,5 kg / Woche 
2: mehr als 1 kg / Woche 
 
17. Krankheitseinsicht 
 
0: Patient erkennt, daß er depressiv und krank ist 
1: Räumt Krankheit ein, führt sie aber auf schlechte  
Ernährung, Klima, Überarbeitung, Virus, Ruhebedürfnis  
usw. zurück 
2: Leugnet Krankheit ab 
 
18. Tagesschwankungen 
 
A. Geben Sie an, ob die Symptome schlimmer am Morgen 
oder am Abend sind. Sofern keine Tagesschwankungen 
auftreten, ist „0“ anzukreuzen. 
 
0: Keine Tagesschwankungen 
1: Symptome schlimmer am Morgen 
2: Symptome schlimmer am Abend 
 
B. Wenn es Schwankungen gibt, geben Sie ihre Stärke an. 
Falls es keine gibt, kreuzen Sie „0“ an. 
 
0: Keine 
1: Gering 
2: Stark 
 
19. Depersonalisation, Derealisation  
      (z.B. Unwirklichkeitsgefühle, nihilistische Ideen) 
 
0: Keine 
1: Gering 
2: Mäßig 
3: Stark 
4: Extrem (Patient ist handlungsunfähig) 
 
20. Paranoide Symptome 
 
0: Keine 
1: Mißtrauisch 
2: Beziehungsideen 
3: Beziehungs- und Verfolgungswahn 
 
21. Zwangssymptome 
 
0: Keine 
1: Gering 
2: Stark 
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SF 36 - Fragebogen zum Gesundheitszustand 
In diesem Fragebogen geht es um Ihre Beurteilung Ihres Gesundheitszustandes. Der Bogen ermöglicht 
es, im Zeitverlauf nachzuvollziehen, wie Sie sich fühlen und wie Sie im Alltag zurechtkommen. 
Bitte beantworten Sie jede der folgenden Fragen, indem Sie bei den Antwortmöglichkeiten die 
Zahl ankreuzen, die am ehesten auf Sie zutrifft. 
1.     Wie würden Sie Ihren Gesundheitszustand im Allgemeinen beschreiben? 
(Bitte kreuzen Sie nur ein Kästchen an!) 
 
p 1. Ausgezeichnet 
p 2. Sehr gut 
p 3. Gut 
p 4. Weniger gut 
p 5. Schlecht 
2.     Im Vergleich zum vergangenen Jahr, wie würden Sie Ihren derzeitigen Gesundheitszustand 
beschreiben? (Bitte kreuzen Sie nur ein Kästchen an!) 
 
p 1. Derzeit viel besser als vor einem Jahr 
p 2. Derzeit etwas besser als vor einem Jahr 
p 3. Etwa so wie vor einem Jahr 
p 4. Derzeit etwas schlechter als vor einem Jahr 
p 5. Derzeit viel schlechter als vor einem Jahr 
3. Im Folgenden sind einige Tätigkeiten beschrieben, die Sie vielleicht an einem normalen Tag 
ausüben. Sind Sie durch Ihren derzeitigen Gesundheitszustand bei diesen Tätigkeiten ein- 
geschränkt? Wenn ja, wie stark? (Bitte kreuzen Sie in jeder Zeile nur ein Kästchen an!) 
 
 Tätigkeiten Ja, stark        Ja, etwas 
eingeschränkt eingeschränkt 
(1)                  (2) 
Nein, überhaupt 
nicht eingeschränkt 
(3) 
a Anstrengende Tätigkeiten, z.B. schnell 
laufen, schwere Gegenstände heben, 
anstrengenden Sport treiben 
P P P 
b Mittelschwere Tätigkeiten, z.B. einen 
Tisch verschieben, staubsaugen, ke- 
geln, Golf spielen 
P P P 
c Einkaufstaschen heben oder tragen P P P 
d Mehrere Treppenabsätze steigen P P P 
e Einen Treppenabsatz steigen P P P 
f Sich beugen, knien, bücken P P P 
g 
Mehr als 1 Kilometer zu Fuß gehen P P P 
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h   Mehrere Straßenkreuzungen weit zu 
Fuß gehen 
P P                    P 
i Eine Straßenkreuzung weit zu Fuß ge- 
hen P P                    P 
j    Sich baden oder anziehen P P                    P 
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4. Hatten Sie in den vergangenen 4 Wochen aufgrund Ihrer körperlichen Gesundheit irgendwelche 
Schwierigkeiten bei der Arbeit oder anderen alltäglichen Tätigkeiten im Beruf bzw. zu Hause? (Bitte 
kreuzen Sie in jeder Zeile nur ein Kästchen an!) 
 
 Schwierigkeiten Ja (1) Nein (2) 
a Ich konnte nicht so lange wie üblich tätig sein. P P 
b Ich habe weniger geschafft als ich wollte. P P 
c Ich konnte nur bestimmte Dinge tun. P P 
d Ich hatte Schwierigkeiten bei der Ausführung (z.B. ich mußte 
mich besonders anstrengen). P P 
5. Hatten Sie in den vergangenen 4 Wochen aufgrund seelischer Probleme irgendwelche Schwierigkeiten 
bei der Arbeit oder anderen alltäglichen Tätigkeiten im Beruf bzw. zu Hause (z.B. weil Sie sich nieder- 
geschlagen oder ängstlich fühlten)? (Bitte kreuzen Sie in jeder Zeile nur ein Kästchen an!) 
 
 Schwierigkeiten Ja(1)    Nein (2) 
a Ich konnte nicht so lange wie üblich tätig sein. P         P 
b Ich habe weniger geschafft als ich wollte. P         P 
c Ich konnte nicht so sorgfältig wie üblich arbeiten. P         P 
6. Wie sehr haben Ihre körperliche Gesundheit oder seelischen Probleme in den vergangenen 4 Wochen 
Ihre normalen Kontakte zu Familienangehörigen, Freunden, Nachbarn oder zum Bekanntenkreis beein- 
trächtigt? (Bitte kreuzen Sie nur ein Kästchen an!) 
 
p 1. Überhaupt nicht 
p 2. Etwas 
p 3. Mäßig 
p 4. Ziemlich 
p 5. Sehr 
7.        Wie stark waren Ihre Schmerzen in den vergangenen 4 Wochen? (Bitte kreuzen Sie nur ein Kästchen an!) 
 
p 1. Ich hatte keine Schmerzen 
p 2. Sehr leicht 
p 3. Leicht 
p 4. Mäßig 
p 5. Stark 
8.        Inwieweit haben die Schmerzen Sie in den vergangenen 4 Wochen bei der Ausübung Ihrer Alltagstätigkei- 
ten zu Hause und im Beruf behindert? (Bitte kreuzen Sie nur ein Kästchen an!) 
 
1. Überhaupt nicht 
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P 2. Ein bißchen 
P 3. Mäßig 
P 4. Ziemlich 
P 5. Sehr 
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9.   In diesen Fragen geht es darum, wie Sie sich fühlen und wie es Ihnen in den vergangenen 4 Wochen gegan- 
gen ist. (Bitte kreuzen Sie in jeder Zeile nur ein Kästchen an!) 
Wie oft waren Sie in den vergangenen 4 Wochen ... 
 
 
Befinden 
Immer 
(1) 
Meistens Ziemlich 
(2)       oft (3) 
Manchmal 
(4) 
Selten 
(5) 
Nie 
(6) 
a ... voller Schwung? P P P P P P 
b ... sehr nervös? P P P P P P 
c ... so niedergeschlagen, daß Sie 
nichts aufheitern konnte? P P P P P P 
d ... ruhig und gelassen? P P P P P P 
e ... voller Energie? P P P P P P 
f ... entmutigt und traurig? P P P P P P 
g ... erschöpft? P P P P P P 
h ... glücklich? P P P P P P 
 
  i 
... müde? P P P P P P 
10. Inwieweit haben Ihre körperliche Gesundheit oder seelische Probleme in den vergangenen 4 Wochen Ihre 
Kontakte zu anderen Menschen (Besuche bei Freunden, Verwandten usw.) beeinträchtigt? (Bitte kreuzen 
Sie nur ein Kästchen an!) 
 
p 1. Immer 
p 2. Meistens 
p 3. Manchmal 
p 4. Selten 
p 5. Nie 
11. Inwieweit trifft jede der folgenden Aussagen auf Sie zu? (Bitte kreuzen Sie in jeder Zeile nur ein Kästchen an!) 
  
a Ich scheine etwas leichter als andere 
krank zu werden. P P P P P 
b Ich bin genauso gesund wie alle 
anderen, die ich kenne P    P P P P 
c Ich erwarte, daß meine Gesundheit 
nachläßt P P P P P 
d Ich erfreue mich ausgezeichneter 
Gesundheit P P P P P 
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Fragebogen zur Lebenszufriedenheit (FLZ) – Teil 1 
 
Im Folgenden geht es darum, wie zufrieden Sie mit den genannten Lebensbereichen im allgemeinen 
sind. Kreuzen Sie bitte jeweils die Zahl an, die für Sie am ehesten zutrifft. 
 
Mir bin mit meiner/m ...  
 Zufriedenheit  
 völlig  
unzufrieden 
sehr  
zufrieden  
1. Gesundheitliche 
Verfassung 
 
0 1 2 3 4 5 6 7 8 9 10 
2. Körperliche 
Leistungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
3. Geistige 
Leistungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
4. Persönliches 
Wohlbefinden 
 
0 1 2 3 4 5 6 7 8 9 10 
5. Selbstwertgefühl 
 
0 1 2 3 4 5 6 7 8 9 10 
6. Entspannungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
7. Erfolg und 
Anerkennung 
 
0 1 2 3 4 5 6 7 8 9 10 
8. Unterstützung und 
Geborgenheit durch 
andere 
 
0 1 2 3 4 5 6 7 8 9 10 
9. Selbständigkeit im 
Alltag 
 
0 1 2 3 4 5 6 7 8 9 10 
10. Ehe / Partnerschaft 
 
0 1 2 3 4 5 6 7 8 9 10 
11. Sexualleben 
 
0 1 2 3 4 5 6 7 8 9 10 
12. Familienleben 
 
0 1 2 3 4 5 6 7 8 9 10 
13. Freundschaften / 
Bekanntschaften 
 
0 1 2 3 4 5 6 7 8 9 10 
14. Berufliche Situation 
 
0 1 2 3 4 5 6 7 8 9 10 
15. Finanzielle Situation 
 
0 1 2 3 4 5 6 7 8 9 10 
16. Wohnsituation 
 
0 1 2 3 4 5 6 7 8 9 10 
17. Freizeit 
 
0 1 2 3 4 5 6 7 8 9 10 
18. Medizinische 
Behandlung 
 
0 1 2 3 4 5 6 7 8 9 10 
19. Umgang mit meiner 
Krankheit 
 
0 1 2 3 4 5 6 7 8 9 10 
20. Leben allgemein 
 
0 1 2 3 4 5 6 7 8 9 10 
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Im Folgenden geht es darum, wie wichtig Ihnen die genannten Bereiche für Ihre allgemeine 
Lebenszufriedenheit sind. Kreuzen Sie bitte jeweils die Zahl an, die für Sie am ehesten zutrifft. 
 
Mir ist mein/e ... bzw. 
Mir sind meine ... 
 Wichtigkeit 
 völlig  
unwichtig 
sehr  
wichtig 
21. Gesundheitliche 
Verfassung 
 
0 1 2 3 4 5 6 7 8 9 10 
22. Körperliche 
Leistungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
23. Geistige 
Leistungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
24. Persönliches 
Wohlbefinden 
 
0 1 2 3 4 5 6 7 8 9 10 
25. Selbstwertgefühl 
 
0 1 2 3 4 5 6 7 8 9 10 
26. Entspannungsfähigkeit 
 
0 1 2 3 4 5 6 7 8 9 10 
27. Erfolg und 
Anerkennung 
 
0 1 2 3 4 5 6 7 8 9 10 
28. Unterstützung und 
Geborgenheit durch 
andere 
 
0 1 2 3 4 5 6 7 8 9 10 
29. Selbständigkeit im 
Alltag 
 
0 1 2 3 4 5 6 7 8 9 10 
30. Ehe / Partnerschaft 
 
0 1 2 3 4 5 6 7 8 9 10 
31. Sexualleben 
 
0 1 2 3 4 5 6 7 8 9 10 
32. Familienleben 
 
0 1 2 3 4 5 6 7 8 9 10 
33. Freundschaften / 
Bekanntschaften 
 
0 1 2 3 4 5 6 7 8 9 10 
34. Berufliche Situation 
 
0 1 2 3 4 5 6 7 8 9 10 
35. Finanzielle Situation 
 
0 1 2 3 4 5 6 7 8 9 10 
36. Wohnsituation 
 
0 1 2 3 4 5 6 7 8 9 10 
37. Freizeit 
 
0 1 2 3 4 5 6 7 8 9 10 
38. Medizinische 
Behandlung 
 
0 1 2 3 4 5 6 7 8 9 10 
39. Umgang mit meiner 
Krankheit 
 
0 1 2 3 4 5 6 7 8 9 10 
40. Leben allgemein 
 
0 1 2 3 4 5 6 7 8 9 10 
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UKU  - Nebenwirkungsskala (Teil 1) 
 
Kategorie der 
Nebenwirkung Symptome 
Grad während der 
letzten 3 Tage 
 
0: nicht vorhanden 
1: vorhanden, leicht 
2: vorhanden, moderat 
3: vorhanden, schwer 
 
Kausaler 
Zusammenhang 
zur Medikation ? 
 
1: unwahrscheinlich 
2: möglich 
3: wahrscheinlich 
 
Typ des 
hauptsächlich 
beschuldigten 
Medikamentes 
 
(s. Liste F1/F2) 
  0 1 2 3 1 2 3  
ps
yc
hi
sc
h 
Konzentrationsschwierigkeiten         
Asthenie / Mattigkeit / gesteigerte 
Ermüdbarkeit 
        
Schläfrigkeit / Sedation         
Gedächtnisschwierigkeiten         
Depression         
Anspannung / innere Unruhe         
verlängerte Schlafdauer         
verkürzte Schlafdauer         
Verstärkte Traumaktivität         
Emotionale Gleichgültigkeit         
ne
ur
ol
og
is
ch
 
Dystonie         
Rigidität         
Hypokinesie / Akinesie         
Hyperkinesie         
Tremor         
Akathisie         
epileptische Anfälle         
Parästhesien         
au
to
no
m
 
Akkomodationsschwierigkeiten         
verstärkter Speichelfluß         
verminderter Speichelfluß         
Übelkeit / Erbrechen         
Diarrhöe         
Obstipation         
Miktionsstörungen         
Polyurie / Polydipsie         
orthostatischer Schwindel         
Palpitationen / Tachykardie         
verstärkte Transpirationsneigung         
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UKU  - Nebenwirkungsskala (Teil 2) 
 
Kategorie der 
Nebenwirkung Symptome 
Grad während der 
letzten 3 Tage 
 
0: nicht vorhanden 
1: vorhanden, leicht 
2: vorhanden, moderat 
3: vorhanden, schwer 
 
Kausaler 
Zusammenhang 
zur Medikation ? 
 
1: unwahrscheinlich 
2: möglich 
3: wahrscheinlich 
 
Typ des 
hauptsächlich 
beschuldigten 
Medikamentes 
 
(s. Liste F1/F2) 
  0 1 2 3 1 2 3  
so
ns
tig
e 
 
Exanthem         
- morbilliform         
- petechial         
- urtikariell         
- psoriatisch         
- nicht zu klassifizieren         
Pruritus         
Photosensibilität         
vermehrte Pigmentierung         
Gewichtszunahme         
Gewichtsverlust         
Menorrhagie         
Galaktorrhöe         
Gynäkomastie         
gesteigerte Libido         
verminderte Libido         
erektile Dysfunktion         
ejakulatorische Störungen         
Orgasmusstörungen         
trockene Vagina         
Kopfschmerzen         
- Spannungskopfschmerz         
- Migräne         
- andere Formen         
physische Abhängigkeit          
psychische Abhängigkeit         
 
Globale Einschätzung der Beeinträchtigung der 
täglichen Leistungsfähigkeit des Patienten 
durch bestehende Nebenwirkungen : 
 
                                                                       Einschätzung durch 
  Patient Arzt 
0 Keine Nebenwirkungen   
1 Leichte Nebenwirkungen ohne Leistungseinbußen 
  
2 Nebenwirkungen mit mäßigen Leistungseinbußen 
  
3 Nebenwirkungen mit starken / merklichen Leistungseinbußen 
  
Konsequenzen : 
 
0 Keine Konsequenzen 
1 
Häufigere Untersuchung des Pat., aber keine 
Dosisreduktion und/oder gelegentliche Behandlung 
der Nebenwirkungen 
2 Dosisreduktion und/oder ständige Behandlung der Nebenwirkungen 
3 Absetzen der Medikation / Wechsel des Präparats 
Kompetenznetzwerk „Depression, Suizidalität“ 
 
 
Patient / Code: H-____-S61-0   Datum: ____-___-20___   Termin A/W/E /K: ____   Rater: ____ 
 
   UKU 3
„Depression,  Suizidalität“ 
 
